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ABSTRACT 
 
THE ROLE OF FLT3 IN HEPATOCELLULAR CARCINOGENESIS 
N. Sumru BAYIN 
M.S. in Molecular Biology and Genetics 
Supervisor: Assist. Prof. Dr. K. Can Akçalı 
July 2010, 82 Pages 
Hepatocellular carcinoma (HCC) is one of the most prevalent cancer types and it 
has a high mortality rate. Its high incidence is a consequence of lack of 
biomarkers that could track the progression of the disease. Identification of a 
marker, which involves in different stages of cancer progression, through fibrosis 
to HCC, would be a good candidate for diagnosis, prediction of prognosis and 
targeted therapies. Therefore we decided to identify a novel marker for HCCs, to 
overcome these consequences. Previously our group has shown that oval cell 
marker FLT3, a known hematopoetic stem cell marker and which is known to be 
constitutively active in many of the leukemias, has a role in liver regeneration. 
Also our immunohistochemical analysis of cirrhotic liver tissues have shown that 
FLT3 is expressed in liver injury. Therefore, we decided to analyze the role of 
FLT3 in hepatocellular carcinogenesis. Expression analysis of FLT3 on mRNA 
and protein level and the expression analysis of adult stem cell, cancer stem cell, 
and epithelial and mesenchymal lineage markers on mRNA level in 14 HCC cell 
lines (HepG2, Hep3B, Hep40, Huh7, PLC/PRF/5, Mahlavu, Focus, Sk-Hep-1, 
Snu182, Snu387, Snu398, Snu423, Snu449, Snu475) was performed. Four of 
these cell lines (Snu182, Snu398, Huh7 and Hep40) were chosen due to their 
different expression levels of FLT3 and the functional role of FLT3 in HCCs was 
assessed by blocking its activity by a small molecule inhibitor K-252a 
Nocardiopsis sp.. Functional studies had shown that upon inhibitor treatment, 
subcellular localization of the protein was changed and its invasion ability in vitro 
was impaired. Also nude mice xenografts had shown that upon inhibitor treatment 
tumor forming ability of FLT3 expressing cells were highly diminished. Therefore 
we suggest that FLT3 has a role in hepatocellular carcinogenesis and it might be 
another link between liver regeneration and hepatocellular carcinogenesis. 
Keywords: Hepatocellular carcinoma, liver Regeneration, FLT3.  
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ÖZET 
FLT3’ÜN KARACİĞER KANSERİNDEKİ ROLÜ 
N. Sumru BAYIN 
Moleküler Biyoloji ve Genetik Yüksek Lisans 
Tez Yöneticisi: Yar. Doç. Dr. K. Can Akçalı 
Temmuz 2010, 82 Sayfa 
Karaciğer kanseri, dünyada en yaygın görülen ve ölüm oranı çok yüksek olan bir 
hastalıktır.  Bu durumunun başlıca sebebi de, kanseri tanısında ve tedavisinde 
etkili olacak genlerin çok iyi tanımlanmamış olmasından kaynaklanır. Karaciğer 
kanserinin fibrozdan baslayan farklı aşamalarında rolü bulunan genelerin 
tanımlanması, kanseri tanısında, seyirinin tespitinde ve tedavisinde önemli 
gelişmeler sağlayacaktır. Bu nedenle yeni bir belirleyici gen bulmayı 
amaçlamaktayız. Grubumuzun daha önceki çalışmasında, oval hücre belirleyicisi 
olan FLT3 geninin karaciğer yenilenmesi sırasında bir rolü olduğu gösterilmiştir. 
FLT3’ün kan kök hücrelerinde bulunduğu ve kan kanserlerinde ifade ve 
aktivitelerinde artış olduğu bilinmektedir. İmunohistokimyasal analizlerimiz ile 
FLT3’ün sirotik karaciğerler de gözlemlediğimiz için, bu genenin karaciğer 
yaralanmalarının yanısıra karaciğer kanserinde de rolü olduğunu düşünmekteyiz. 
Bu amaçla, 14 karaciğer kanseri hücre hattında (HepG2, Hep3B, Hep40, Huh7, 
PLC/PRF/5, Mahlavu, Focus, Sk-Hep-1, Snu182, Snu387, Snu398, Snu423, 
Snu449, Snu475), FLT3’ün mRNA ve protein düzeyinde, diğer erişkin kök hücre 
ve kanser kök hücresi belirleyicilerinin de mRNA düzeyinde ifadelerini araştırdık. 
Daha sonra FLT3 ifadesinin çeşitliliğine göre 4 hücre hattı (Snu182, Snu398, 
Huh7 ve Hep40) belirleyip, bunlarda FLT3 inhibitörü kullanarak, genin 
fonksiyonunu inceledik. Inhibitör, protenin hücre içindeki yerini değiştirmekle 
birlikte, bu hücrelerin in vitro ortamda yayılmalarında da değişikliğe sebep 
olmuştur. Bunun yanı sıra çıplak farelerdeki zenograft deneyleri, FLT3 ifadesi 
gösteren hücrelerin inhibitöre maruz kaldıklarında tümör oluşturma etkilerinde 
büyük ölçüde azalma görülmüştür. Bu sonuçlar bize FLT3’in karaciğer 
kanserlerinde önemli rol oynadığını göstermekte ve FLT3’ün karaciğer 
yenilenmesi ve kanseri arasında bir bağ kurabileceğini düşündürmektedir. 
Anahtar Kelimeler: Karaciğer kanseri, karaciğer yenilenmesi, FLT3. 
 
 iv 
ACKNOWLEDGEMENTS 
I would like to express my gratitude to my supervisor Assoc. Prof. Dr. Can Akçalı 
for his personal and academic guidance and for his trust in me. I hope I didn’t let 
him down, in any part of this study. It was an honor for me to work with him. 
I would like to thank the present and former members of Akçalı Group, Zeynep 
Tokcaer Keskin, Fatma Ayaloğlu Bütün, Verda Bitirim, Sinan Gültekin and 
Hande Koçak for their friendship, support and patience in answering my endless 
questions. I couldn’t accomplish this without their help. 
I would like to thank to Assist. Prof Dr. Cengiz Yakıcer for his ideas and support 
during this thesis research. Also I would like to thank to Tolga Acun for his help 
and providing the cell lines.  
I would like to thank to Assoc. Prof. Dr. İhsan Gürsel for his supervision and 
members of İG group for their help. 
I would like to thank to MBG faculty, for providing me the necessary background 
that I will need in my future endeavors.  
I would like to thank to Chigdem, Aslı, Ceren, Gizem, Emre, my classmates and 
all the MBG family members, who made this journey joyful and easy, for their 
support, friendship and help.  
I would like to thank The Scientific and Technological Research Council of 
Turkey (TÜBİTAK) for their financial support throughout my studies with 
BIDEB 2210 Scholarship. 
I would like to thank to Aslı, Begüm, Elvan, Gizem and Nil for being more than 
friends. Finally, I would like to thank to my dear parents for always believing in 
me and for supporting my decisions no matter what.  
 v 
TABLE OF CONTENTS 
ABSTRACT.................................................................................................................................. II 
ÖZET ...........................................................................................................................................III 
ACKNOWLEDGEMENTS.........................................................................................................IV 
TABLE OF CONTENTS ............................................................................................................. V 
LIST OF TABLES....................................................................................................................VIII 
LIST OF FIGURES.................................................................................................................. IXX 
ABBREVIATIONS.....................................................................................................................XI 
1. INTRODUCTION ....................................................................................................................1 1.1 LIVER.....................................................................................................................................................2 
1.1.1 Liver Development.................................................................................................................... 2 
1.1.2 Liver Anatomy and Histology .............................................................................................. 4 
1.1.3. Epithelial­Mesenchymal Transitions............................................................................... 7 
1.1.4 Liver Regeneration................................................................................................................... 9 
1.1.5 Liver Fibrosis.............................................................................................................................10 
1.1.6 Cirrhosis ......................................................................................................................................11 
1.1.7 Hepatocellular Carcinoma..................................................................................................11 1.2 FMS‐LIKE TYROSIN KINASE (FLT3) ...........................................................................................14 
1.2.1 Structure of FLT3....................................................................................................................14 
1.2.2 FLT3 Signal Transduction...................................................................................................15 
1.2.3 Physiological Functions of FLT3.......................................................................................17 
1.2.4 Pathophysiological Functions of FLT3 ..........................................................................18 
2. AIM OF THE STUDY...........................................................................................................20 
3. MATERIALS AND METHODS ..........................................................................................21 3.1 CELL CULTURE .................................................................................................................................21 
3.1.1 K­252a Treatment of HCC cell lines ................................................................................21 
 vi 
3.2 NUDE‐MICE TUMOR XENOGRAFTS ..............................................................................................21 3.3 STANDARD BUFFERS AND SOLUTIONS.........................................................................................22 3.4 TOTAL RNA ISOLATION .................................................................................................................22 3.5 CDNA SYNTHESIS............................................................................................................................23 3.6 REVERSE TRANSCRIPTASE‐POLYMERASE CHAIN REACTION (RT‐PCR) .............................23 
3.6.1 Multiplex PCR for Sip1/Zeb2 and GAPDH ....................................................................26 
3.6.2 Agarose Gel Electrophoresis...............................................................................................27 3.7 PROTEIN ISOLATION .......................................................................................................................27 
3.7.1 Total Protein Isolation..........................................................................................................27 
3.7.2 Protein Quantification with Bradford Assay...............................................................28 3.8 WESTERN BLOTTING ......................................................................................................................28 
3.8.1 SDS­Polyacrylamide Gel Electrophoresis (SDS­PAGE) ...........................................28 
3.8.2 Transfer of Proteins to the PVDF Membrane..............................................................29 
3.8.3 Immunological Detection of Immobilized Proteins .................................................30 3.9 IMMUNOSTAINING PROCEDURES...................................................................................................31 
3.9.1 Immunohistochemistry Staining for Paraffin Embedded Tissue Sections .....31 
3.9.2 Immunoflourescense Staining for Frozen Tissue Sections....................................32 
3.9.3 Immunoflourescense Staining...........................................................................................32 3.10 WOUND HEALING ASSAY.............................................................................................................33 3.11 TUNEL ASSAY ..............................................................................................................................33 3.12 SENESCENCE ASSOCIATED Β‐GAL ASSAY (SABG) .................................................................34 3.13 STATISTICAL ANALYSIS……………………..…………………………………………………………35 
4. RESULTS...............................................................................................................................36 4.1 CHARACTERIZATION OF HCC CELL LINES ..................................................................................36 
4.1.1 Expression Pattern of FLT3 in HCC Cell Lines ............................................................36 
4.1.2 Expression Analysis of Adult Stem Cell, Cancer Stem Cell and Hematopoietic 
Lineage Markers in 14 HCC Cell Lines.......................................................................................38 
4.1.3 Expression Analysis of Epithelial and Mesenchymal Lineage Markers in 14 
HCC Cell Lines with RT­PCR...........................................................................................................39 4.2 EXPRESSION OF FLT3 IN CIRRHOTIC AND NORMAL HUMAN LIVER .....................................39 
 vii 
4.3 FUNCTIONAL ANALYSIS OF FLT3 IN HCCS BY INHIBITING THE PHOSPHORYLATION OF THE PROTEIN WITH K‐252A ........................................................................................................................41 
4.3.1.  Effect of K­252a on the cellular morphology in HCCs...........................................42 
4.3.2 Effect of K­252a on the Subcellular Localization of FLT3 in HCCs ...................42 
4.3.3 Wound Healing Assay ...........................................................................................................44 
4.3.4 Change in the Epithelial and Mesenchymal Lineage Markers After Inhibitor 
Treatment .............................................................................................................................................48 
4.3.5 In vitro Programmed Cell Death Analysis and Senescence Associated β­Gal 
Assay ........................................................................................................................................................49 4.4 IN VIVO TUMORIGENESIS ................................................................................................................52 
5. DISCUSSION.........................................................................................................................57 5.1 DISCUSSION.......................................................................................................................................57 5.2 FUTURE PERSPECTIVES ..................................................................................................................66 
6. REFERENCES .......................................................................................................................67 
7. APPENDIX............................................................................................................................76 
 
 
 viii 
LIST OF TABLES 
TABLE 3. 1 PRIMERS USED FOR EXPRESSION ANALYSIS IN RT‐PCR......................................................................24 TABLE 3. 2 REACTION MIXTURE FOR RT‐PCR .........................................................................................................25 TABLE 3. 3 REACTION MIXTURE OF SIP1‐GAPDH MULTIPLEX RT‐PCR...............................................................26 TABLE 3. 4 BSA STANDARD CURVE FOR BRADFORD ASSAY....................................................................................29 TABLE 3. 5 ANTIBODIES USED FOR WESTERN BLOTTING ANALYSIS. ....................................................................30 TABLE 3. 6 SECONDARY ANTIBODIES USED IN WESTERN BLOTTING....................................................................30 TABLE 3. 7 PREPARATION OF SABG SOLUTION .......................................................................................................35 TABLE 3. 8 PREPARATION OF NA‐P BUFFER.............................................................................................................35 TABLE 5. 1 FINDINGS OF IN VITRO AND IN VIVO EXPERIMENTS ...............................................................................65  
 
 
 
 
 
 
 
 
 
 
 
 
 ix 
LIST OF FIGURES 
FIGURE 1. 1 FLOWCHART SHOWING THE EMBRYONIC DEVELOPMENT OF THE LIVER ........................................... 4 FIGURE 1. 2 STRUCTURE OF A LIVER LOBULE .............................................................................................................. 5 FIGURE 1. 3 A CLOSER VIEW OF THE LIVER LOBULE AND CELL TYPES FOUND IN THE LIVER ................................ 6 FIGURE 1. 4 MOLECULAR MARKERS INVOLVED IN EPITHELIAL MESENCHYMAL TRANSITION ........................... 8 FIGURE 1. 5 MECHANISMS FOR HEPATOCELLULAR CARCINOGENESIS ...................................................................12 FIGURE 1. 6 FLT3 STRUCTURE....................................................................................................................................15 FIGURE 1. 7 DOWNSTREAM EFFECTORS OF FLT3 ...................................................................................................19 FIGURE 4. 1 EXPRESSION PROFILING OF FLT3 WITH RT‐PCR .............................................................................37 FIGURE 4. 2  WESTERN BLOTTING ANALYSIS WITH FLT3 ANTIBODY ...................................................................37 FIGURE 4. 3 EXPRESSION PROFILING OF 14 HCC CELL LINES FOR ADULT STEM CELL, CANCER STEM CELL AND HEMATOPOIETIC CELL LINEAGE MARKERS. .....................................................................................................38 FIGURE 4. 4 RT‐PCR ANALYSIS FOR EPITHELIAL AND MESENCHYMAL LINEAGE MARKERS. ............................39 FIGURE 4. 5 FLT3 IMMUNOHISTOCHEMISTRY OF A NORMAL LIVER......................................................................40 FIGURE 4. 6 FLT3 IMMUNOHISTOCHEMISTRY OF A CIRRHOTIC LIVER. .................................................................41 FIGURE 4. 7   INVERTED MICROSCOPY PHOTOS OF SNU182 AND SNU398 AFTER 200NM INHIBITOR TREATMENT FOR TWO HOURS. ..........................................................................................................................42 FIGURE 4. 8  FLT3 IMMUNOFLOUROSCENCE.............................................................................................................43 FIGURE 4. 9 PHOTOGRAPHS OF WOUND HEALING ASSAY FOR SNU182.................................................................44 FIGURE 4. 10 STATISTICAL ANALYSIS OF WOUND HEALING CAPACITY OF SNU182..........................................45 FIGURE 4. 11 PHOTOGRAPHS OF WOUND HEALING ASSAY FOR SNU398..............................................................46 FIGURE 4. 12 STATISTICAL ANALYSIS OF WOUND HEALING CAPACITY OF SNU398  .........................................46 FIGURE 4. 13 PHOTOGRAPHS OF WOUND HEALING ASSAY FOR HUH7  .................................................................47 FIGURE 4. 14 STATISTICAL ANALYSIS OF WOUND HEALING CAPACITY OF HUH7 ..............................................48 FIGURE 4. 15  RT‐PCR ANALYSIS OF EPITHELIAL AND MESENCHYMAL LINEAGE MARKERS AFTER 200NM K‐252A TREATMENT FOR TWO HOURS................................................................................................................49 FIGURE 4. 16 THE RATIO OF APOPTOTIC INDICES OF INHIBITOR TREATED CELLS AND DMSO TREATED CELLS................................................................................................................................................................................50 FIGURE 4. 17  SABG STAINING OF SNU182, SNU398, HUH7 AND HEP40.........................................................51 FIGURE 4. 18 XENOGRAFT TUMORS OF SNU398......................................................................................................53 FIGURE 4. 19 XENOGRAFT TUMORS OF HEP40.  ......................................................................................................54 FIGURE 4. 20 XENOGRAFT TUMORS OF HUH7. .........................................................................................................55 
 x 
FIGURE 4. 21 AVERAGE TUMOR VOLUMES OF XENOGRAFTS INJECTED WITH SNU398, HEP40 AND HUH7 CELLS IN THE PRESENCE OR ABSENCE OF INHIBITOR. ....................................................................................56 FIGURE 5. 1 FLT3’S INVOLVEMENT DURING DIFFERENT STAGES LEADING TO HCC...........................................64  
 
 
 
 xi 
ABBREVIATIONS 
 
2-AAF: N-2-acetylaminofluorene 
AML: Acute Myloid Leukemia 
BMP: Bone Morphogenic Proteins 
bp: base pair 
BSA: Bovine Serum Albumin 
cDNA: complementary DNA 
CSC: Cancer Stem Cell 
DC: Dendritic Cell 
ddH2O: double distilled water 
DMEM: Dulbecco’s Modified Eagle Medium 
DNA: deoxyribonucleic acid 
DNAse: Deoxribonuclease 
EMT: Eptihelial-Mesenchymal Transition 
ESC: Embryonic Stem Cell 
FLT3: Fms-like Tyrosine Kinase 3 
FLT3L: FLT3 Ligand 
HBV: Hepatitis B Virus 
 xii 
HCC:  Hepatocellular Carcinoma 
HCV: Hepatitis C Virus 
HGF: Hepatocyte Growth Factor 
ITD: Internal Tandem Duplication 
kDa: Kilo Dalton 
MET: Mesenchymal-Epithelial Transition 
MSC:  Mesenchymal Stem Cell 
μL: Microliter 
mL: Milliliter 
nM: nanoMolar 
NS: non-significant 
OD: Optical Density 
PH: Partial Hepatectomy 
pmol: picomol  
RNA: ribonucleic acid 
rpm: revolution per minute 
RPMI: Roswell Park Memorial Institute medium 
RTK: Receptor Tyrosine Kinase 
RT: Room Temperature 
 xiii 
RT-PCR: Reverse Transcriptase Polymerase Chain Reaction 
TKD: Tyrosine Kinase Domains 
TUNEL: Terminal d-UTP Nick End Labeling 
X-Gal: 5-bromo-4-chloro-3-indolyl-β-D-galactoside 
 
 1 
1. Introduction 
 Its functional importance and regenerative capacity make liver one of the 
most interesting organ in the body. Liver was considered as the principle organ 
and the first organ to be formed in the fetus by the medieval scientists 
(http://www.stanford.edu/class/history13/earlysciencelab/body/liverpages/livergal
lbladderspleen.html). Its regenerative capacity has been recognized even earlier 
times, illustrated by the ancient Greek legend of Prometheus. In the myth of 
Prometheus, after stealing the fire from Zeus for the mortals, he had been 
punished by being tied in a rock in Caucasus Mountain and having a part of its 
liver eaten by a great eagle. According to the myth his liver was regenerating 
everyday so that the eagle can eat it (Michalopoulos and DeFrances, 1997). 
Liver is very important for the survival of the organism and perturbation 
of its functions causes very severe consequences. Only cure for its end-stage 
diseases is the liver transplantation. Among these conditions, Hepatocellular 
Carcinoma (HCC) has one of the highest incidence rates all over the world. HCC 
is the second most lethal cancer after pancreatic cancer according to the statistics 
of 2005. Even more alarming is the fact that incidence and death rates from HCC 
are increasing since 1980s and there is an estimated 18.910 liver cancer deaths in 
America for the year 2010 (American Cancer Society, 
http://www.cancer.org/downloads/STT/Cancer_Facts _and_Figures_2010.pdf).  
Lack of biomarkers for early prognosis, as well as targeted therapies and 
resistance to chemotherapeutic agents are some of the important reasons of its 
high incidence and lethality.  
This drawback has urged us to identify a candidate marker for HCC. Fms-
like Tyrosine Kinase (FLT3) is a hematopoietic stem cell marker, which is 
important for the development of the hematopoietic cells and also its aberrant 
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functioning leads to different types of leukemia. Although it seems there is no 
close relation between FLT3 and the liver, as we trace the steps of liver 
development, liver regeneration and HCC throughout this thesis, the relation will 
reveal itself, and the rationale behind this thesis can be easily understood. 
Introduction section starts with a brief explanation of the liver 
development. Then the anatomy and the functioning units of the liver and the 
different types of cells found in the liver will be explained. Later on, processes of 
liver regeneration, fibrosis and HCC will be discussed and the role of FLT3 and 
epithelial-mesenchymal transition will be mentioned in each context. Finally, the 
structural and functional properties of FLT3 will be analyzed. 
1.1 Liver 
 Liver is the largest organ in the body and its functions and structure make 
it a vital organ throughout the development and the adult life. Liver has several 
important functions such as glycogen storage, drug detoxification, cholesterol and 
urea metabolism, the production and secretion of hormones (such as Insulin-like 
Growth Factor, Angiotensinogen and Thrombopoietin) as well as plasma proteins 
such as Albumin and Apolipoproteins. In addition to its endocrine function, liver 
also has exocrine secretion in the form of bile (Si-Tayeb et al, 2010). 
1.1.1 Liver Development 
Throughout the development and during the adult life, stem cells play very 
important roles in the maintenance of the tissues both anatomically and 
physiologically. Stem cells are specialized cells that are capable of self-renewing 
themselves and differentiating into cells of different lineages.  During 
development, embryonic stem cells (ESC) are found in the inner cell mass of the 
blastula of a day 4 embryo. These cells are pluripotent stem cells that are able to 
give rise to a whole organism, except the extra-embryonic tissues in mammalian 
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development (Evans and Kaufman, 1981; Martin, 1981). As the development 
proceeds, the first liver bud is observed in embryonic day 8.5, which expresses 
some hepatic markers such as Albumin and Hnf4a, a transcription factor, which is 
expressed in early hepatic cells (Bort et al, 2006).   
As the embryonic day 8.5 is reached in mammalian development, the 
signals from the septum transversum mesenchyme direct the tissue specific 
foregut endodermal progenitor cells to differentiate into liver bud and form the 
hepatoblast. The collective effect of fibroblast growth factors from the cardiac 
mesoderm and bone morphogenic proteins (BMP) from the septum transversum 
exhibits their function by the activation of transcription factors such as Hex, 
GATA and FoxA. Hex has an evolutionary role in the development of the liver 
bud and it is activated by SMAD1 and SMAD4, which make it a direct target of 
BMP signaling (Zhang et al, 2007). GATA and FoxA function during the 
remodeling of the chromatin structure in the promoter region of Albumin. 
Coordinately, the development of the hepatic vasculature is very important for the 
expansion of the liver bud (Zhao and Duncan, 2005). The Kupffer cells derived 
from the yolk sac emerge in the sinusoidal capillaries (Enzan et al, 1983) and 
hepatic stellate cells are also derived from septum transversum mesenchymal cells 
(Wandzioch et al, 2004). 
 There are a wide variety of signals involved in the liver development. The 
major signal involved in liver growth is Wnt signaling, which promotes the 
formation of bipotential liver progenitor cells. These cells eventually differentiate 
in two different cell lineages: (1) hepatocytes and (2) cholangiocytes on 
embryonic day 16, via Notch signaling and hepatocyte growth factor (HGF) 
signaling respectively. Besides Notch and HGF signaling, TGF-β also provides 
necessary signals for the growth of the fetal liver (Mishra et al, 2009) (Figure 1.1). 
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Figure 1. 1 Flowchart showing the embryonic development of the liver (adapted from Mishra 
et al, 2009) 
  During development, fetal liver is also the primary site for hematopoiesis 
between embryonic day 11.5 and 16.5, which suggest a close relationship between 
the hematopoietic cells and the hepatic parenchyma. The interchange of signals 
between the hematopoietic cells within the fetal liver and the hepatocytes are 
crucial for the development of both cell types. Oncostatin M secreted from 
hematopoietic cells induces hepatocyte differentiation via increased HNF4α 
expression and co-culturing of fetal hepatocytes with hematopoietic cells showed 
increased growth and proliferation of hematopoietic cells (Kinoshita et al, 1999).  
 FLT3 is hematopoietic lineage marker and FLT3 signaling stimulates 
myeloid and lymphoid progenitor cell proliferation. The close relation of 
hematopoietic stem cells during liver development and hematopoiesis also implies 
that FLT3 signaling can also function in the interplay of these two processes.  
1.1.2 Liver Anatomy and Histology 
Liver consists of lobules, which contains hepatocytes, vascular tissues and 
bile ducts.  Hepatocytes are the most abundant cell type in liver. Portal vein and 
hepatic artery supply the blood through the sinusoidal capillaries (Figure 1.2). 
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Figure 1. 2 Structure of a liver lobule (Si-Tayeb et al, 2010) 
Although the parenchyma of the liver is hepatocytes, there are many other 
cell types in the liver to fulfill its function. Other than hepatocytes, liver consists 
of cholangiocytes (biliary epithelial cells), endothelial cells, sinusoidal endothelial 
cells, Kupffer cells (resident liver macrophages), pit cells (natural killer cells), and 
hepatic stellate cells (Figure 1.3). 
Approximately 78% of the paranchyme volume of the liver is hepatocytes 
(Blouin et al, 1977). Hepatocytes are epithelial cells, and they perform most of the 
functions of the liver ranging from protein secretion, bile secretion, detoxification, 
cholesterol, urea and glucose/glycogen metabolisms.  
Cholangiocytes are located in the duct epithelium of the liver and their 
main function is to form the bile ducts for the transport of bile. The physical 
properties such as the rate of the bile flow and the pH of the bile are controlled by 
cholangiocytes. Also they have the ability to secrete water and bicarbonate to 
contribute to liver homeostasis. 
Endothelial cells form the vasculature of the liver, and supply the blood. 
Sinusoidal endothelial cells help the detoxification of the liver by transferring 
molecules, proteins and macromolecule wastes between serum and hepatocytes.  
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Pit cells and Kupffer cells involve in the immune functions of the liver. Pit 
cells perform cytotoxic activity and the kupffer cells secrete cytokines and 
proteases and they are the antigen presenting cells (Si-Tayeb et al, 2010). 
Finally hepatic stellate cells maintain the extracellular matrix, and most 
importantly they contribute to the regeneration process through hepatic fibrosis, 
where the activation of stellate cells leads fibrosis. Also they are sites for retinoic 
acid storage (Friedman, 2008).  
 
Figure 1. 3 A closer view of the liver lobule and cell types found in the liver (adapted from 
Freidman, 2008) 
 
On the other hand, in adult liver, there are hepatic progenitor cells, which 
lie in the Canals of Herring, the biliary trees of the liver, in direct contract with 
the hepatocytes and bile duct cells. These cells are equivalent to the rodent “oval 
cells” (Sell and Leffer, 2008; Mishra et al, 2009).  
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Oval cells express a wide range of markers, which include hepatocyte 
lineage markers, cholangiocyte lineage markers and even some hematopoietic 
lineage markers such as c-kit (Mishra et al, 2009) and FLT3 (Aydin et al, 2007) 
(Figure 1.1).  
These bipotential progenitor cells, which express markers of both fetal 
hepatocytes and biliary cells, are able to differentiate into both lineages. They 
have the ability to differentiate into hepatocytes and biliary cell but they can only 
perform this action when the hepatocyte proliferation is stalled, as in the case of a 
toxic chemical exposure to induce liver regeneration (Fausto and Campbell, 
2003). Therefore these cells have critical importance in the success of 
regeneration process.  
Upon the injury, survival of the organism partly depends on a biological 
process called Epithelial-Mesenchymal Transition (EMT).  
1.1.3. Epithelial-Mesenchymal Transitions  
Epithelial-Mesenchymal Transition (EMT) is a normal physiological 
process that takes place during embryonic development. The reverse process of 
the EMT is called Mesenchymal-Epithelial Transition (MET). EMT/MET during 
embryogenesis is responsible for the formation mesodermal and endodermal 
mesenchyme, secondary epithelia and more. These two processes define changes 
in the cell’s shape and adhesive properties not their cell fate. The process involves 
a change in the genetic programming of the polarized epithelial cells into mobile 
mesenchymal cells. Epithelial cells are polarized cells with apical and basolateral 
sides, and they are tightly attached to each other with tight and adherens junctions. 
Mesenchymal cells on the other hand form when the epithelial cells loose their 
apico-basolateral polarity and junctions. Many markers are established to 
differentiate epithelial and mesenchymal cells. Loss of E-cadherin (E-cad) is a 
global marker for EMT (Figure 1.4) (Kalluri and Weinberg, 2009).  
 8 
EMT/MET is observed during embryogenesis (Type 1 EMT), wound 
healing/tissue regeneration/organ fibrosis (Type 2 EMT) and neoplasia (Type 3 
EMT) (Kalluri and Weinberg, 2009; Choi and Diehl, 2009). In our context, we 
will concentrate on its involvement in tissue regeneration and neoplasia. 
 
Figure 1. 4 Molecular Markers involved in Epithelial Mesenchymal Transition (Kalluri and 
Weinberg, 2009) 
 
During injury and fibrosis, as the inflammation response is activated and 
sustained, EMT produces fibroblastic cells that cause progressive fibrosis.  Which 
cells undergo EMT to produce fibroblasts is controversial but there are evidences 
for hepatocytes that undergo EMT via TGF-β1 stimulation (Zeisberg et al, 2007). 
Not only hepatocytes but also cholangiocytes are also undergoing EMT upon 
fibrosis and this process is regulated by Hedgehog signaling (Omenetti et al, 
2008). 
 The outcome of the EMT/MET process during fibrosis is critical for the 
repair process. If the incidence of MET is more, this means that epithelial cells are 
formed, which are hepatocytes and cholangiocytes in this case, the repair 
successful and regeneration is achieved but if EMT predominates the process, 
excessive fibrosis occurs (Choi and Diehl, 2009). 
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1.1.4 Liver Regeneration 
 Besides its important functions mentioned above, liver is a unique organ 
with its regenerative capacity. Liver regeneration can be induced by partial 
hepatectomy (PH) or liver injury by CCl4 treatment (Hermandez-Munoz et al, 
1990), which induces hepatocyte death and fibrosis.  
PH is the surgical procedure first defined by Higgins and Anderson in 
1931, where 2/3 of the livers of the animals are removed. Upon this procedure in 
rodents, it is observed that animals can restore their original liver volume in a 
week and then stop regenerating. Also liver performs this action by not producing 
a new lobe, but by increasing the volume of the existing lobe/lobes (Taub, 2004). 
This technique is still being widely used in liver regeneration experiments.  How 
liver maintains its volume and how this regeneration is enabled are still questions 
that need to be answered, although the evidences are accumulating. There are 
different types of mechanisms involved in the liver regeneration upon PH. These 
can be summarized as: 
• Replication of existing hepatocytes: Hepatocytes are normally non-
dividing cells, but when subjected to PH, remaining 95% of the hepatocytes re-
enter into the cell cycle, to restore the liver volume (Michalopoulos and 
DeFrances, 1997). 
• Progenitor cell-dependent regeneration: After some types of 
injuries, such as intraperitoneal injection of D-galactosamine (GaIN) or treatment 
with N-2-acetylaminofluorene (2-AAF), hepatocytes cannot proliferate. In such 
cases, the progenitor cells of the liver proliferate and differentiate into mature 
hepatocytes (Dabeva and Shafritz, 1993). These progenitor cells are namely oval 
cells (in rodents) or hepatic progenitor cells (in human) (Taub, 2004). 
• Homing of bone marrow derived mesenchymal stem cells (MSC) 
to the site of injury: When MSCs isolated from bone marrow of the rats are 
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labeled and reinjected to rats with liver injury, they are found to be located in the 
site of injury (Zhou et al, 2010). The driving force for this homing is not clear yet 
but some chemokines and cytokines are suspected to function. 
Previously our group has shown that oval cell marker FLT3, functions 
during the progenitor cell-dependent regeneration. The intracellular localization of 
the protein changes upon PH. This suggests that FLT3 could be required for the 
activation of the repair process (Aydin et al, 2007).  
1.1.5 Liver Fibrosis 
Fibrosis is the state of the tissue, where accumulated extracellular matrix 
proteins change the tissue architecture in response to injury. Upon hepatic injury, 
and the activation of the regeneration signal, hepatic stellate cells become 
activated and gain a myofibroblastic phenotype (Freidman, 2008).  These 
activated myofibroblasts secrete a wide range of matrix proteins especially 
collagen, in order to participate the wound healing process of the liver and induce 
an inflammation response. Recent advances have also shown that stellate cell 
driven myofibroblasts are not the only source of the matrix protein secretion but 
portal fibroblasts and myofibroblasts from the bone marrow also participate in 
fibrosis. Myofibroblast activation is achieved mainly by TGF-β signaling 
(Gressner and Weiskirchen, 2006).   
Following chronic liver injury, besides activation of stellate cells and 
proliferation of myofibroblasts, fibrosis leads to; accumulation of extracellular 
matrix proteins in between sinusoidal endothelial cells and hepatocytes, activation 
of Kupffer cells and infiltration of lymphocytes for inflammation response, 
apoptosis of the hepatocytes and an increase in resistance to blood flow through 
the sinusoidal endothelial cells. Finally extensive fibrosis leads to liver cirrhosis 
(Baraller and Brenner, 2005). 
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1.1.6 Cirrhosis  
 The clinic description of cirrhosis is the replacement of normal liver 
lobules with abnormal nodules separated by fibrous tissue.  As liver reaches end-
stage fibrosis, the diagnosis of cirrhosis can be made (Garcia-Tsao et al, 2009). 
Cirrhosis leads to portal hypertension and end-stage liver disease. Hallmarks of 
cirrhotic liver are reduced hepatocyte volume and imbalanced accumulation of 
extracellular matrix components, as in the case of fibrosis, but more progressive. 
 The foremost treatment for cirrhosis is liver transplantation. But the 
limitations against this treatment have urged new therapeutical approaches mainly 
consisting of stem cell therapies, which aim to complement the loss of 
hepatocytes and excessive extracellular matrix accumulation (Chen et al, 2010). 
 One interesting study that is aimed to show the mechanisms behind the 
end stage cirrhosis has revealed that the molecular markers for cirrhosis vary due 
to the starting reason of the disease. For example, MHC Class I C-4 subunit was 
found to be upregulated in cirrhotic livers caused by the Hepatitis C Virus, when 
compared to other cirrhotic tissues. Also many inflammation related genes were 
found to be upregulated in cirrhosis (McCaughan et al, 2000).  
 The reasons that cause cirrhosis can also result in HCC eventually. This is 
achieved by the gain of telomerase activation of the hepatocytes in the cirrhotic 
liver (Farazi and DePinho, 2006).   
 
1.1.7 Hepatocellular Carcinoma 
Major factors that lead to the development of HCC are chronic hepatitis B 
and C infection, excessive alcohol consumption, aflatoxin-B1 exposure and 
progressive cirrhosis. These risk factors have different mechanisms for 
hepatocellular carcinogenesis (Figure1.5) (Farazi and DePinho, 2006).  
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The hallmarks of liver cancers are the loss of cell cycle regulation due to 
mutations or genetic aberration in key regulators of cell cycle such as p53, p16, 
Retinoblastoma (Rb) or Cyclin D1, excessive angiogenesis due to increased 
vascular endothelial growth factor (VEGF), platelet derived growth factor 
(PDGF) signaling, increase in anti-apoptotic signals (Farazi and DePinho, 2006), 
TERT activation for immortality (LLovet and Bruix, 2008). In addition, copy 
number variations or epigenetic reprogramming are also observed in HCC 
(Villanueva et al, 2007). 
 
Figure 1. 5 Mechanisms for Hepatocellular carcinogenesis (Farazi and DePinho, 2006) 
Finally, the involvement of cancer stem cells (CSCs) also contributes to 
the progression of HCC. In the case of HCC there isn’t a single marker for CSC. 
Liver CSC can be identified by their CD133 positivity (Yin et al, 2007), OV6 (a 
hepatic progenitor marker) positivity (Yang et al, 2008), EpCAM and Alfa-
fetaprotein double positivity (Yamashita et al, 2009), CD90 and CD45 double 
positivity (Yang et al, 2008) or by isolating the side population cells (Chiba et al, 
2006). 
 
 13 
1.1.7.1 Epithelial-Mesenchymal Transitions and Hepatocellular Carcinoma 
Type 3 EMT is observed during tumorigenesis and is associated with 
increased invasiveness and metastasis of the primary tumors. The epithelial 
carcinoma cells acquire a mesenchymal phenotype, which is confirmed by the 
loss of E-Cadherin and gain of the expression of some mesenchymal markers such 
as α-smooth muscle actin and vimentin. These mesenchymal cells are responsible 
for the metastasis of the tumors. The invasion-metastasis cascade consists of 
intravasation, transport via circulation, extravasation at the site of metastasis, 
finally formation of micrometastases. Eventually secondary epithelial tumors are 
formed when the migrating mesenchymal cells undergo MET. The signals that 
derive this metastatic cells is still unclear but involvement of TGF-β, growth 
factor signaling via RTKs such as epidermal growth factor (EGF), and platelet 
derived growth factor (PDGF) and epigenetic reprogramming are well established 
(Kalluri and Weinberg, 2009).  
Besides giving tumor cells an invasive and metastatic phenotype, recent 
data have also shown that the cells undergone EMT gain some stemness features. 
EMT in tumors not only induces metastasis but they also induce drug resistance. 
The intersections between the pathways involved in EMT and activated in stem 
cells are strong evidences for the relation between EMT and CSCs. For example 
in the case of CSCs of the breast cancer (CD44+CD24-/low), these metastatic 
cells found to be expressing TGF- β, and when TGF- β signaling is inhibited, they 
become epithelial like. This suggests that as TGF- β, signals involved in EMT can 
also be important in CSC’s maintenance (Singh and Settleman, 2010). 
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1.2 Fms-Like Tyrosin Kinase (FLT3) 
 Throughout previous sections, relations between FLT3 and liver 
development and liver regeneration have been explained. For better 
understanding, in this section the FLT3 signaling will be analyzed in detail. 
1.2.1 Structure of FLT3 
Fms-like tyrosine kinase 3 is a type III tyrosine kinase (RTK) which is 
also known as fetal liver kinase-2 (FLK-2) and stem cell kinase-1 (STK-1), was 
first isolated as a hematopoietic stem cell marker (Matthews et al, 1991). It was 
shown that stem cells and progenitor cell populations expressed high FLT3 
despite its absence in mature cells (Matthews et al, 1991). Human FLT3 is located 
on chromosome 13q12 and its mouse counterpart is located on chromosome 5, 
region G (Rosnet et al, 1991). The gene codes 993 amino acid length protein with 
85% amino acid sequence homology between human FLT3 and mouse FLT3 
(Rosnet et al, 1993). FLT3 contains five immunoglobulin like extracellular 
domains, a transmembrane domain, a juxtamembrane domain and two 
intracellular tyrosine kinase domains (TKDs) linked by a kinase insert, whose 
functions vary from ligand recognition, receptor activation and signal transduction 
(Figure 1.6). The protein exists in two forms, one is the glycosylated membrane 
bound form, which is 160kDa, and the other is the 130kDa protein, which is not 
membrane bound (Lyman et al, 1993). 
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Figure 1. 6 FLT3 Structure The orientation of the protein in the phospholipid bilayer and the 
domains can be seen. 
1.2.2 FLT3 Signal Transduction 
1.2.2.1 FLT3 Ligand (FLT3L) 
Activated FLT3 functions as a dimer, where its phosphlorylation is 
achieved via the tyrosine kinase domains. In order to form a dimer, due to the 
steric hindrance issues, the receptor needs to change confirmation which is 
enabled by ligand binding that leads to the phoshorylation and activation of the 
receptor. The ligand specific for FTL3 is FLT3 Ligand; FLT3-L.  The 
chromosomal location of the gene coding the FLT3L is 19q13.3-13.4 and it codes 
a type I transmembrane protein, which is secreted as a soluble homodimeric 
protein and shown to induce proliferation of FLT3 transfected cells. Mouse 
FLT3L was cloned in 1993 (Lyman et al, 1993) and human counterpart was 
cloned in 1994 (Hannum et al, 1994).  Although the expression of FLT3 is 
restricted to early progenitors of hematopoietic cells, thymus, lymph nodes 
(Rosnet et al, 1993) and placenta, brain, gonads (Maroc et al, 1993), FLT3L 
shows a wider range of expression in many tissues of different origins. This 
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suggests that the effect of FLT3 signaling is controlled by the restricted 
expression of FLT3 (Drexler and Quentmeier, 2004). 
1.2.2.2 Activation of the Receptor and FLT3 Signaling 
Suggested action mechanism of FLT3L is paracrine signaling where 
activation could occur through direct contact with the neighboring cells or via 
local secretion. The close proximity of early progenitors expressing FLT3 and the 
low concentration of the ligand in the normal serum samples also supported this 
mechanism. An autocrine feedback loop is also another scenario due to the co-
expression of the receptor and the ligand (Brasel et al, 1995) 
Upon ligand binding, FLT3 changes confirmation and forms a homodimer, 
which brings the kinase domains in close proximity for phosphorylation. After 
dimerization, the downstream signaling is initiated following by internalization 
and subsequent degradation of the complex. These processes happen very quickly 
where the first degraded products of the FLT3L-FLT3 complex is seen within 20 
minutes after stimulation (Turner et al, 1996). Various intracellular signaling 
pathways are activated via the active FLT3 (Figure 1.7). Chimeric protein analysis 
with FMS-FLT3 RTKs has shown that FLT3 interacts SH2 domain containing 
proteins for phosphorylation docking sites and these sites can interact with 
different signaling molecules such as phophatidylinositol 3-kinase (PI3K) and 
growth factor receptor-bound protein 2 (Grb2; an adaptor protein). PI3Ks 
downstream effectors are protein kinase B (PKB/AKT), mammalian target of 
rapamycin (mTOR) and those of Grb2 are mitogens activated kinase (MAPK) 
pathway elements. Both these pathways induce transcription and translation of 
crucial regulatory genes involved in proliferation and block apoptosis via post-
translational modifications to pro-apoptotic proteins such as BCL2 family of 
proteins (Stirewalt and Radich, 2003). 
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Similar to all forms of tyrosine kinase signaling, FLT3 signaling 
participates in many physiological processes through out embryogenesis and 
development. In addition, due to their ability to activate many downstream 
signaling pathways involved in cell cycle progression and prevention of apoptosis, 
tyrosine kinases are one of the most studied molecules for cancer therapies. Many 
therapeutic agents for inhibiting the kinase activity of these proteins have been 
identified and many more are under investigation. The high incidence of FLT3 
mutations in AML and some other blood malignancies marked FLT3 as a good 
candidate for potential therapies against these cancer types. There are ongoing 
phase III trials and the combination of these with the conventional chemotherapies 
gives promise to the prognosis of cancer with FLT3 mutations (Sanz et al, 2009). 
Also there are small molecules, which inhibit the tyrosine kinase activity 
of the protein such as K-252a. Phase II/III clinical trials for AML are continuing 
for such small molecule inhibitors of FLT3 (Cools et al, 2004). 
1.2.3 Physiological Functions of FLT3 
As stated earlier, FLT3 signaling is shown to stimulate the proliferation of 
myeloid and lymphoid progenitor cells. Besides being a hematopoietic lineage 
marker, FLT3 and its ligand FLT3L have some important physiological roles in 
the immune system by inducing dendritic cell (DC) development, which are 
antigen-presenting cells. DCs are generated from FLT3 expressing early myeloid 
or lymphoid progenitors and stimulation with FLT3L is essential for the 
development of DCs (Wu and Liu, 2007). FLT3-FLT3L interactions are also 
important for T-cell development in the thymus. Thymic recovery is maintained 
by FLT3L expressing perivascular fibroblasts which are in close proximity to the 
thymic entry site of FLT3 expressing progenitor cells for T-cell production 
(Kenins et al, 2010). Other than its role on immunity, FLT3 also has a role in the 
maintenance of neural stem cell populations. It is highly expressed in some 
regions of embryonic central nervous system (CNS) such as spinal cord and 
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dorsal root ganglia. However, contrary to its proliferative effects during 
embryonic development, FLT3 inhibits the neural stem cell proliferation but 
promotes neuronal survival, upon ligand activation with neural growth factor 
(NGF) (Brazel et al, 2001). These various responses of cells to FLT3 activation 
may be due to the various secondary signaling molecules activated and interplay 
of other signaling molecules in the cellular microenvironment. But which 
response to give still remains a mystery.  
Hepatic bipotential progenitor cell (oval cell in rodents) marker FLT3, also 
functions in liver regeneration. In rat liver regeneration models, upon PH and 2-
AAF treatment, FLT3 is expressed in hepatocytes in different time points after 
PH. Also in early hours after PH, FLT3 is localized in the membrane but later it 
changes its localization and becomes cytoplasmic (Aydin et al, 2007) which 
suggests that postranslational mechanisms such as translocation may play 
important roles in FLT3 activity during regeneration.  
1.2.4 Pathophysiological Functions of FLT3 
 Since FLT3’s proliferative and anti-apoptotic role on the cells are 
established, it is not surprising to observe its aberrant expression in cancers. It was 
first described in hematopoietic malignancies such as acute myeloid leukemia 
(AML), where the first mutations of FLT3 were identified.  One of the first 
identified and mostly observed mutations is the internal tandem duplication (ITD) 
mutation. ITDs vary between 3 to >400 base pairs, rely in exons 14 and 15. This 
site corresponds to the juxtamembrane domain and tyrosine kinase domain 
(Nakao et al, 1996).  ITDs lead to a constitutively active protein, where the 
ongoing proliferative and anti-apoptotic signal leads to cancer formation. It was 
shown that 20.4% of AML patients exhibited ITD (Thiede et al, 2002).  Other 
than ITD, missense point mutations in exon 20 of the tyrosine kinase domain had 
been shown as a common mutation also. These mutations reside in the codon 835 
of the gene and are associated with 7.7% of the AML patients. In addition to these 
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common ones, there are other mutations, which are collectively found in approx. 
25-45% of AML patients (Stirewalt and Radich, 2003). Although they have 
smaller frequencies, many other mutations of FLT3 are also associated with 
different forms of leukemia other than AML. 
 
Figure 1. 7 Downstream Effectors of FLT3 (Stirewalt and Radich, 2003) 
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2. Aim of the Study 
 HCC is one of the most highly seen and lethal cancers all over the world. 
Lack of biomarkers for early prognosis, as well as targeted therapies and 
resistance to chemotherapeutic agents are some of the important reasons of its 
high incidence and lethality.  
 There are strong evidences that show a link between the disease and risk 
factors such as HBV, HCV infection, aflotoxins and excessive alcohol 
consumption. However the molecular mechanisms of the progression of HCC are 
not well characterized. This lack of characterization also halts the formation of 
good diagnostic and prognostic markers. In addition, possible links between liver 
regeneration and HCC are not explored in detail. The molecular signature of 
different stages of fibrosis, cirrhosis and HCC will reveal good candidates for 
diagnostic and therapeutic purposes.  
 Therefore we aimed to come up with a new marker for HCC, which can 
differentiate between different stages of the disease ranging from fibrosis to 
cirrhosis and cancer. Such a marker will also be helpful to predict the prognosis of 
the disease. 
 FLT3, which is a hematopoietic stem cell marker, is also an oval cell 
marker FLT3 and previously our group has shown its importance in liver 
regeneration. Also the close relation between fetal liver and hematopoiesis and the 
pathways activated by FLT3 made it a good candidate for analysis. Therefore, we 
hypothesize that FLT3 might be the link between the liver regeneration and 
hepatocellular carcinogenesis. By investigating the function of FLT3 in vitro and 
in vivo hepatocellular carcinoma models, we aimed to show its role in 
hepatocellular carcinogenesis.  
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3. Materials and Methods 
3.1 Cell Culture 
 14 different HCC (Hep3B, HepG2 Hep40, Huh7, PLC/PRF/5, Mahlavu, 
Sk-Hep1, Focus, Snu182, Snu387, Snu398, Snu423, Snu449 and Snu475) cell 
lines and HEK293 cell lines were used during this study. Hep3B, HepG2 Hep40, 
Huh7, PLC/PRF/5, Mahlavu, Sk-Hep1 and Focus cell lines were cultured in Low-
glucose DMEM. Snu182, Snu387, Snu398, Snu423, Snu449 and Snu475 were 
cultured in RPMI1640 (HyClone, Utah, USA) Both media were supplemented 
with 10%FBS, 100U/ml penicillin-streptomycin and 0.1mM non-essential amino 
acids (HyClone, Utah, USA). Cells were incubated at 37°C with 5% CO2 and 
media were changed every 3 days. For cryopreservation 90% FBS, 10% DMSO 
mixture was used for freezing medium and cells were stored at -80°C for several 
months or at liquid nitrogen storage tank for longer periods of time. 
3.1.1 K-252a Treatment of HCC cell lines 
 FLT3 inhibitior (K-252a Nocardiopsis sp., Calbiochem) was added to the 
culturing media of Snu182, Snu398, Huh7 and Hep40 cell lines at 200nM 
concentration and treated for 2 hours prior to further experiments. As control 
group, these cells were cultured for 2 hours with same volume of DMSO. 
3.2 Nude-Mice Tumor Xenografts 
             Snu182, Snu398, Huh7 and Hep40 cells that were either treated with K-
252a or DMSO (as explained in section 3.1.1) were tyrpsinated and then pelleted 
at 1500rpm for 5 minutes, washed with 1xPBS, counted and re-pelleted. Final 
pellets were dissolved in 1xPBS and aliquoted at a concentration of 6x106 
cells/250μL. For each group, 5 nine-month-old male nude mice (CD1) were used. 
In order to eliminate differences in each animal, cells treated with inhibitor were 
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subcutaneously injected to the right side of the animals whereas control cells were 
injected to the left side of the animal. Tumor sizes were measured on regular 
periods. Significance of the differences in tumor sizes was calculated with 
student’s t-test. The animals were housed under controlled environmental 
conditions (22ºC) with a 12-hour light and 12 hour dark cycle in the animal 
holding facility of the Department of Molecular Biology and Genetics at the 
Bilkent University. This study protocol complied with Bilkent University Local 
Ethic Committee (BILHADYEK) guidelines on humane care and use of 
laboratory animals. The animals were permitted unlimited access to food and 
water at all times. 
3.3 Standard Buffers and Solutions 
 Ingredients of the standard solutions and buffers mentioned throughout the 
Materials and Methods section is given in Section 6. Appendix. 
3.4 Total RNA Isolation 
 When the cells were more than 80% confluent, they were trypsinated at 
37°C for 3-5 minutes. Then trypsin was inhibited with fresh media (DMEM or 
RPMI depending on the cell line) and cells were pelleted at 1500rpm for 5 
minutes. Pellet was re-suspended with 1xPBS and pelleted again. RNA isolation 
was performed by RNeasy Midi Kit (QIAGEN, Hilden, GERMANY) according 
to the manufacturer’s protocol. The concentrations and the OD260 and OD280 
values of the RNA samples were measured by NanoDrop ND-1000 (NanoDrop 
Technologies, USA). RNA denaturating gel electrophoresis was performed to 
check the integrity of the RNAs and presence of DNA contamination. 
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3.5 cDNA Synthesis 
 cDNAs were synthesized from the isolated total RNA samples by using 
DyNAmo cDNA Synthesis Kit (Finnzymes, FINLAND). 2μg RNA was used for 
each reaction with a total volume of 40μL. RNA was diluted with DEPC-ddH2O 
with a total volume of 14μL, then 2μL of oligodT primer was added. This mixture 
was incubated at 65°C for 5 minutes and chilled on ice for 3-5 minutes. Then 
20μL 2X Reverse Transcriptase Reaction Buffer and 4μL M-MulV RT RnaseH 
enzyme was added to each reaction. Conditions for cDNA synthesis were 25°C 
for 10 minutes, 45°C for 45 minutes and 85°C for 5 minutes. 
3.6 Reverse Transcriptase-Polymerase Chain Reaction 
(RT-PCR) 
 Primers were designed by using the online Primer3 tool v.0.4.0 
(http://frodo.wi.mit.edu/primer3/) and NCBI primer BLAST tool 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). The list of the primers used 
during this study is shown on Table 3.1.  
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Table 3. 1 Primers used for expression analysis in RT-PCR 
Gene 
Name 
Product 
Size 
Forward Primer (5’-3’) Reverse Primer (5’-3’) 
Tm 
(°C) 
FLT3 set 1 114 bp GGAAGAAGAGGAGGACTTA AGGTCTCTGTGAACACACGA 60 
FLT3 set 2 184 ATGGATTCGGGCTCACCT GCTGATTGACTGGGATGC 60 
CD133 183 AATGACCCTCTGTGCTTGGT GGATTGATAGCCCTGTTGGA 60 
CD34 187 GGCCACAACAAACATCACAG AACATTTCCAGGTGACAGGC 60 
CD90 124 TGACCCGTGAGACAAAGAAG GTGAAGGCGGATAAGTAGAG 60 
CD45 217 TTGGCTTTGCCTTTCTGGAC TGGGTGGAAGTATTGTCTGG 60 
LGR5 195 GGAGCATTCACTGGCCTTTA ATTGTCATCCAGCCACAGGT 60 
E-cadherin 119 GACTCGTAACGACGTTGCAC GGTCAGTATCAGCCGCTTTC 60 
Vimentin 110 GCAGGAGGAGATGCTTCAGA ATTCCACTTTGCGTTCAAGG 60 
Fibronectin 108 AATATCTCGGTGCCATTTGC CAGTAGTGCCTTCGGGACTG 60 
α-SMA 165 TATCAGGGGGCACCACTATG GCTGGAAGGTGGACAGAGAG 60 
Sip1/ZEB2 132 TGTAGATGGTCCAGAAGAAATGAA TTGGCAAAGTATTCCTCAAAATCT 60 
GAPDH 
multiplex  
611 AGTCAACGGATTTGGTCGTATT GTAGAGGCAGGGATGATGTTCT 60 
GAPDH 119 GGCTGAGAACGGGAAGCTTGTCAT CAGCCTTCTCCATGGTGGTGAAGA 60 
  
The reaction mixture that was used in RT-PCR analysis is shown in table 
3.2. Buffers and enzymes were supplied from Finnzymes, FINLAND. 
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Table 3. 2 Reaction mixture for RT-PCR 
Ingredient Volume (μL) 
cDNA 1  
10x Taq Reaction Buffer 2.5  
10mM dNTP 0.5  
50mM MgCl2  0.75  
Forward Primer (10pmol) 1 
Reverse Primer (10pmol) 1 
Taq Polymerase (1U) 0.5   
ddH2O 17.75  
Total 25 
 
RT-PCR was performed with the following conditions for all of the primers 
except GAPDH, for GAPDH, reaction was performed for 23 cycles; 
 
Initial denaturation: 95°C 5 minutes 
   94°C  30 sec 
             60°C 30 sec                  30 cycles 
   72°C 30 sec 
Final extension:      72°C 5 minutes  
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3.6.1 Multiplex PCR for Sip1/Zeb2 and GAPDH 
 The reaction mixture that was used in Multiplex PCR analysis is shown in 
table 3.3.  
Table 3. 3 Reaction mixture of Sip1-Gapdh multiplex RT-PCR 
Ingredients Volume (μL) 
cDNA 1 
10x Reaction Buffer 2.5 
10mM dNTP 0.6 
50mM MgCl2 0.75 
Sip1 Forward primer (10 pmol) 2 
Sip1 Reverse primer (10 pmol) 2 
Gapdh Forward primer (10pmol) 0.15 
Gapdh Reverse primer (10pmol) 0.15 
Taq Polymerase 0.5 
dd-H2O 15.35 
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The following conditions were used for the reaction. 
Initial denaturation: 95°C 5 minutes 
   94°C  30 sec    
   60°C 30 sec 35 cycles 
   72°C 30 sec 
Final extension:      72°C 5 minutes  
3.6.2 Agarose Gel Electrophoresis 
 1.5% agarose gel was prepared with 1XTAE Buffer and ethidium bromide 
(30ng/mL). Samples were prepared with 6X Agarose Gel Loading Dye (1X in 
final mixture) and loaded on gel, which ran at 120V for 25 minutes. Visualization 
was performed by Transilluminator (Vilber Lourmat, FRANCE) and photos were 
taken with ChemiCap software. As a marker, Gene Ruler DNA Ladder Mix (MBI 
Fermantas, Ontario, CANADA) was used. 
3.7 Protein Isolation   
3.7.1 Total Protein Isolation 
 Cells were scraped in 1XPBS and pelleted after centrifugation at 1500 rpm 
for 5 minutes in order to preserve the extracellular proteins. Total protein isolation 
was performed by re-suspending the pellet in Lysis Buffer (Appendix), whose 
amount depends on the size of the pellet (approx. 200 μL). The pellet was 
homogenized and incubated on ice with occasional vortexing for complete lysis. 
Then the cell lysate was centrifuged at 13.000 rpm for 20 minutes at +4°C. 
Supernatants were collected and protein concentration was measured with 
Bradford Assay.  
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3.7.2 Protein Quantification with Bradford Assay 
 Standard curve for Bradford Assay was performed with different 
concentrations of Bovine Serum Albumin (Sigma, Montana, USA). As blank for 
samples, lysis buffer was used. OD was measured at 595nm wavelength, with 
Beckman DU 640 Spectrophotometer and concentrations were calculated 
according to the standard curve obtained for BSA results. Table 3.4 shows the 
preparation of the standard curve. Protein samples with unknown concentrations 
were prepared as 2μL protein, 98μL ddH20 and 900μL Bradford Reagent.  
3.8 Western Blotting 
3.8.1 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 Depending on the size of the protein to be analyzed, different 
concentrations of resolution gel (10% (for proteins in the range of 40 and 90kDa) 
and 7.5% (for proteins larger than 90 kDa)) and 5% stacking gels were prepared. 
25μL of 30μg protein was loaded to the gels. Proteins samples were prepared with 
cracking buffer, by denaturating at 90°C for 5 minutes. Two different types of 
prestained protein markers were used. For proteins with higher molecular size, 
Fermantas Spectra Multicolor Broad Range Protein Ladder (MBI Fermantas, 
Ontario, CANADA) and for smaller proteins, Fermantas PageRuler Prestained 
Protein Ladder (MBI Fermantas, Ontario, CANADA) was used. Gels were run at 
80-120V with cold 1X Running Buffer.  Before transfer, stacking gel was 
removed and gel was gently washed with ddH2O. Then it was put into transfer 
buffer. The size of the protein also determined the type of the transfer that needed 
to be performed.  
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Table 3. 4 BSA standard curve for Bradford Assay  
BSA 
standard  
1(μL) 2(μL) 3(μL) 4(μL) 5(μL) 6(μL) 7(μL) 8(μL) 9(μL) 10(μL) 
BSA 
(1μg/μL) 
0 2.5 5 7.5 10 12.5 15 20 25 35 
ddH2O 100 97.5 95 92.5 90 87.5 85 80 75 65 
Bradford 
Reagent 
900 900 900 900 900 900 900 900 900 900 
 
3.8.2 Transfer of Proteins to the PVDF Membrane  
 Four whatman papers and PVDF Transfer Membrane (0.45μm, Thermo 
Scientific, USA) were cut at the size of the gel and membrane was treated with 
methanol for 30 seconds and ddH2O for 2 minutes. 
3.8.2.1 Semi-Dry Transfer For Proteins around 40-100kDa 
Two whatman papers, membrane, gel and two more whatman papers were 
carefully aligned in BioRad Semi-Dry transfer apparatus (Bio-Rad, California, 
USA). Transfer was performed at a constant current, with 3.5mA for 1 cm2 of the 
membrane for 45 minutes. Then the gel was moved into Commasie Solution for 
detecting the efficiency of the transfer for 30 minutes and then destained.  
Membrane was put into 1X TBS-T (01%) for 5 minutes. 
3.8.2.2 Wet Transfer for Proteins with molecular weight larger than 100kDa 
Two whatmans, membrane, gel and two more whatmans were aligned in 
between sponges of BioRad gel tank (Bio-Rad, California, USA) and soaked into 
Wet Transfer buffer. Overnight transfer was performed at 16 V at 4°C. Then the 
gel was moved to Commasie Solution for detecting the efficiency of the transfer 
for 30 minutes and then destained.  Membrane was put into 1X TBS-T (01%) for 
5 minutes. 
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3.8.3 Immunological Detection of Immobilized Proteins 
Blocking of the membrane was performed for 2-4 hours in non-fat dry 
milk powder block. Then the membrane was incubated overnight with primary 
antibody at 4°C. Primary antibodies and the conditions that were used for western 
blotting studies are shown in table 3.5. The membrane was gently rotated on a 
shaker during these steps. 
Table 3. 5 Antibodies used for Western Blotting analysis.  
Protein 
Name Brand 
Catalog 
no. 
Incubation 
time and 
temperature 
(°C) 
Source 
Molecular 
Weight 
(kDa) 
Antibody 
concentration 
used 
FLT3 Cell Signaling Technology 3462 o/n at +4 
Rabbit 
(mAb*) 130-160 
1/1000 in 
5%BSA block 
Calnexin SantaCruz Biotechnologies sc-6465 o/n at +4 
Goat 
(pAb**) 90 
1/1000 in 
5%non-fat dry 
milk block 
(*mAb: monoclonal antibody, **pAb: polyclonal antibody, o/n: over night) 
After primary antibody incubation, membrane was washed three times 
with TBS-T (1%) for 10 minutes. Secondary antibody incubation was performed 
at RT for one hour. HRP-linked secondary antibodies and the conditions that were 
used during western blotting are shown in table 3.6. Secondary antibodies were 
also prepared in 5% non-fat dry milk block. 
Table 3. 6 Secondary Antibodies used in Western Blotting 
Antibody Brand Catalog no. Dilution Factor 
Anti-Rabbit IgG Cell Signaling 
Technology 
7074 1/2000 
Anti-mouse IgG SantaCruz 
Biotechnologies 
sc-2318 1/2500 
Anti-goat IgG SantaCruz 
Biotechnologies 
sc-2033 1/5000 
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After secondary antibody incubations, membrane was washed three times 
with TBS-T (0.1%) for 10 minutes. The membrane was then treated with 
SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific, 
USA), as stated in manufacturer’s protocol. Then membrane was placed on a 
glass, covered with stretch film and placed in film cassette (Amersham Life 
Sciences, New Jersey, USA). Film was developed with Hyperprocessor 
(Amercham Life Sciences, New Jersey, USA). 
3.9 Immunostaining procedures 
 For immunostaining procedures, anti-FLT3 antibody (sc-340, SantaCruz 
Biotechnologies, California, USA) was used at 1/200 concentration in blocking 
solution. 
3.9.1 Immunohistochemistry Staining for Paraffin Embedded 
Tissue Sections 
 Paraffin embedded tissue sections were de-parafinized in xylene for 15 
minutes. Sections were then treated with decreasing concentrations of EtOH for 
hydration and washed with ddH2O. Antigen retrieval was performed in sodium 
citrate buffer for 10 minutes at 90°C. Then slides were cooled to RT and washed 
with PBS-T (0.1%). After 30 minutes of 3% H2O2 incubation and washing with 
PBS-T, one hour blocking was performed in a humidified chamber. Primary 
antibody (FLT3 in 1/200 dilution) incubation was performed overnight at +4°C. 
After washing once more with PBS-T, slides were treated with Biotin-link Anti-
mouse & Anti-Rabbit IgG (DakoCytomation, Glostrup, Denmark) and with 
Streptavidin-HRP red solution (DakoCytomation, Glostrup, Denmark) for 30 
minutes respectively. Slides were washed with PBS-T and were incubated with 
DAB+Chromogen Substrate (DakoCytomation, Glostrup, Denmark) until the 
staining was observed (2-5 minutes). To stop the color development, tap water 
was applied to the slides. For counter staining, they were dipped in to 
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hematoxylene for 1 minute, and again washed with tap water. Specimens were 
mounted with Faramount Aqueous Mounting Medium (DakoCytomation, 
Glostrup, Denmark), with coverslips (Deckglaser 100 no.1 12mm). The photos 
were taken with light microscope Leica TCS/SP5, Japan. 
3.9.2 Immunoflourescense Staining for Frozen Tissue Sections 
Frozen sections were fixed with 4% paraformaldeyde for 30 minutes and 
then washed with PBS-T (0.1%). After 30 minutes of 3% H2O2 incubation and 
washing with PBS-T, one hour blocking was performed in a humidified chamber. 
Primary antibody (FLT3 in 1/200 dilution) incubation was performed overnight at 
+4°C. After washing once more with PBS-T, slides were treated with 1/200 FITC-
tagged anti-Rabbit IgG (Sigma, Montana, USA) for one hour at RT in dark. 
Specimens were mounted with UltraCruz mounting medium with DAPI 
(SantaCruz Biotechnologies, California, USA) for counter staining. Slides were 
observed in fluorescent microscopy (Leica TCS/SP5, Japan). Excitation 
wavelength for FITC and DAPI was at 490nm and at 359nm respectively. 
3.9.3 Immunoflourescense Staining 
 Cells were grown on coverslips prior to staining. When they were 
approximately 80% confluent, medium was removed and washed with 1X PBS. 
The cells were fixed with cold methanol for 15 minutes. After washing with PBS-
T (0.1%), 10 minutes of 3% H2O2 incubation was performed. After washing with 
PBS-T, coverslips were covered with blocking solution and incubated for one 
hour at RT. Primary antibody (FLT3 in 1/200 dilution) incubation was performed 
at RT for one hour. FITC-tagged anti rabbit IgG (SantCruz Biotechnologies, 
California, USA) was used as secondary antibody at a concentration of 1/200 
dilution in blocking solution. The incubation was performed in dark for one hour 
at RT. Coverslips were mounted with UltraCruz mounting medium with DAPI 
(SantaCruz Biotechnologies, California, USA) for counter staining. Slides were 
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observed in fluorescent microscopy (Leica TCS/SP5, Japan). Excitation 
wavelength for FITC and DAPI was at 490nm and at 359nm respectively.  
3.10 Wound Healing Assay  
 Cells were seeded on 6-well plates, in ~80% confluency. When cells were 
100% confluent, 3 vertical scratches were made with a standard 200μL 
micropipette tip. For convenience, 2 vertical lines were drawn with marker in 
order to take photos of the same region each time. After the scratches were made, 
medium was changed either with medium containing 10% FBS or 2% to mimic 
serum starvation and 200nM K-252a treatment is performed for two hours or two 
days. For 0 hour groups, photos were taken immediately. When two-hour 
inhibitor incubation completed, fresh medium (either with 10% FBS or 2% FBS) 
was added. Mediums of samples, which undergo two-day inhibitor treatment, 
were not changed. Equal volume of DMSO was used in control groups. Wounds 
were monitored for 48 hours and photos of the same regions were taken with 24-
hour intervals. The healed wound distance was measured by calculating the 
difference between the initial and final wound size and dividing it by 2. 
Measurements were taken from 10 different points and significance was 
calculated with student’s t-test among inhibitor treated and control groups for both 
normal medium conditions and serum starvation conditions separately.  
3.11 TUNEL Assay 
 TdT- (terminal deoxynucleotidyl transferase) mediated fluorescein-dUTP 
labeling kit (Roche Diagnostics, Mannheim, Germany) was used to detect DNA 
fragmentation. Cells seeded on coverslips were treated with K-252a for two hours. 
DMSO is used for control groups. Then cells were washed with 1XPBS and fixed 
with freshly prepared 4% paraformaldehyde, for one hour at RT. After washing 
with 1xPBS for three times, cells were treated with freshly prepared and cooled 
permeabilisation (0.1%Triton X-100, 0.1% sodium citrate) solution for two 
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minutes on ice. Then cells were washed with 1XPBS again and 30μL TUNEL 
Reaction mixture was added and incubated at 37°C in dark in a humidified 
chamber for one hour. Coverslips were mounted with UltraCruz mounting 
medium with DAPI (SantaCruz Biotechnologies, California, USA) for counter 
staining. Slides were observed in fluorescent microscopy (Leica TCS/SP5, Japan). 
Excitation wavelength for FITC and DAPI was at 490nm and at 359nm 
respectively. As negative control slides were incubated in the absence of terminal 
deoxynucleotidyl transferase. As positive control, 10 minutes of DNaseI 
(Fermantas, Ontarino, CANADA) treatment is performed at RT, prior to the 
incubation with TUNEL reaction mixture. 
3.12 Senescence Associated β-Gal Assay (SABG) 
 50% confluent cells were treated with K-252a for two hours before 
fixation. Control groups were treated with equal amount of DMSO. Then cells 
were washed with 1XPBS and fixed with freshly prepared 4%paraformaldehyde 
for 15 minutes. After washing with 1XPBS, cells were incubated with freshly 
prepared and filtered SABG solution (Table 3.7), whose pH was adjusted to 6.0 
with Na-P Buffer (Table 3.8) for 18 hours in dark at 37°C. After the incubation, 
cells were washed twice with 1XPBS and fixed with cold methanol for 5 minutes. 
As a counter stain, nuclear fast red was used for 5 minutes. Cover slips were 
washed with ddH2O and closed with DAKO mounting medium (DakoCytomation, 
Glostrup, Denmark). The photos were taken with light microscope Leica 
TCS/SP5, Japan. 
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Table 3. 7 Preparation of SABG Solution 
Stock Solution For 3mL of SABG Solution (μL) 
200 mM Citric Acid (pH:6.0) 600 
Na-P Buffer (pH:6.0) 600 
100mM Potassium Ferrocyanide 150 
100mM Potassium Ferricyanide 150 
2M NaCl 225 
100mM MgCl2 60 
40mg/ml X-gal 75 
ddH2O 1140 
 
Table 3. 8 Preparation of Na-P Buffer (pH: 6.0, Total Volume: 40mL) 
1M Na2HPO4 10.2mL 
1M NaH2PO4 29.8mL 
3.13 Statistical Analysis 
 Student’s t-test from Microsoft Excel 2008 for Mac (Version 12.1.0) is 
used. T-test is performed between inhibitor treated groups and control groups for 
wound healing assay (Section 3.10), TUNEL assay (Section 3.11) and nude mice 
xenograft’s tumor sizes (Section 3.2). Significance threshold is set to 0.05, for p-
value. P-values larger than 0.05 are indicated as non-significant (NS).
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4. Results 
 We used both in vitro and in vivo models to reach our specific aim, which 
is to show the role of FLT3 in hepatocellular carcinogenesis. Firstly in vitro, we 
used 14 established HCC cell lines, and characterized these cells lines with FLT3 
and other adult stem cell, cancer stem cell, hematopoietic stem cell markers and 
epithelial and mesenchymal lineage markers. Then according to their FLT3 
expression levels, we chose 4 different cell lines and continued our functional 
studies to investigate the role of FLT3. For this purpose we used an FLT3 
phosphorylation inhibitor, K-252a to inhibit its function and tested some 
parameters such as cellular morphologies, subcellular localization of FLT3, in 
vitro invasion, change in the expression of epithelial and mesenchymal lineage 
markers and change in their apoptotic cell numbers and induction of senescence. 
Then to further understand FLT3’s involvement in tumorigenesis, we used nude 
mice xenograft models. 
4.1 Characterization of HCC Cell Lines 
We examined the expression profile of FLT3 as well as a panel of adult 
stem cell, cancer stem cell, hematopoietic lineage markers and EMT markers at 
our HCC cell lines. These cell lines were either well differentiated (WD) or poor 
differentiated (PD) HCCs.  WD HCCs (HepG2, Hep3B, Hep40, HUH7 and PLC) 
resemble highly of differentiated hepatocytes, on the other hand PD HCCs 
(Mahlavu, Focus, SK-Hep-1, Snu182, Snu387, Snu398, Snu423, Snu449 and 
Snu475) show characteristics of non-differentiated cells (Qin and Tang, 2002).  
4.1.1 Expression Pattern of FLT3 in HCC Cell Lines 
We checked the expression of FLT3 at the transcript level in 14 HCC cell 
lines by using RT-PCR. Among them, we found that FLT3 mRNA is expressed in 
Hep40, Snu182 and Snu398 cell lines (Figure 4.1). Hep40 is a well-differentiated 
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HCC, whereas Snu182 and Snu398 cell lines are poor differentiated HCC. We 
used GAPDH as loading control. No expression is observed in negative control. 
 
Figure 4. 1 Expression Profiling of FLT3 with RT-PCR  
We performed western blot analysis in order to analyze the FLT3 protein 
in HCC cell lines. We found 130kDa non-glycosylated form of the FLT3 protein 
expression in WD HCCs Hep3B, Hep40, and PD HCCs Focus, SK-Hep1, 
Snu182, Snu387 and Snu398 (Figure 4.2). We used Calnexin for loading control. 
 
Figure 4. 2  Western blotting analysis with FLT3 antibody of  (A) WD HCC cell lines and (B) 
PD HCC cell lines. Calnexin is used as loading control (WD: well differentiated, PD: poor 
differentiated). 
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4.1.2 Expression Analysis of Adult Stem Cell, Cancer Stem Cell 
and Hematopoietic Lineage Markers in 14 HCC Cell Lines 
 In order to assess stemness features of 14 HCC cell lines, we performed 
RT-PCR analysis for the markers of adult stem cell (CD90, LGR5), cancer stem 
cell (CD133) and hematopoietic lineage (CD34, CD45) markers. (Figure 4.3) 
Figure 4. 3 Expression Profiling of 14 HCC cell lines for adult stem cell, cancer stem cell and 
hematopoietic cell lineage markers. 
 Our expression analysis has shown that CD133, an hematopoietic 
progenitor marker, which was recently associated with cancer stem cells (Gupta et 
al, 2009) was expressed in mainly WD HCC cell lines (HepG2, Hep3B, Hep40, 
Huh7 and PLC) and some of the PD HCC cell lines (Mahlavu, Focus, Snu182, 
Snu449). On the other hand, CD90 positivity mainly observed in PD HCC cell 
lines (Focus, SK-Hep-1, Snu387 and Snu398). Lgr5 showed a similar pattern with 
CD133. It was expressed in WD HCCs (HepG2, Hep3B, Huh7) and PD HCC 
Snu182. Finally when the expression of hematopoietic lineage markers 
expressions were analyzed via RT-PCR, it was observed that all of the HCC cell 
lines were negative for CD45, and only Snu182 was positive for CD34. We used 
GAPDH as loading control. No expression was observed in negative control. 
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4.1.3 Expression Analysis of Epithelial and Mesenchymal Lineage 
Markers in 14 HCC Cell Lines with RT-PCR 
 In order to investigate to which lineage does these HCC cell lines belong, 
we analyzed 4 different markers for EMT (Figure 4.4). E-cadherin was used as 
epithelial marker and Fibronectin, Vimentin and α-SMA were used as 
mesenchymal markers. The expressions levels of vimentin and α-SMA did not 
reveal any significant difference between 14 HCC cell lines, but expression of E-
cad was restricted to mainly well WD HCC cell lines and Snu182. On the other 
hand, all the cell lines expressed Fibronectin, although its levels were variable 
highly, especially between Snu182 and Snu398. We used GAPDH as loading 
control. No expression was observed in negative control. 
Figure 4. 4 RT-PCR analysis for Epithelial and Mesenchymal lineage markers. 
 
4.2 Expression of FLT3 in Cirrhotic and Normal Human 
Liver 
 We examined the FLT3 expression in normal (Figure 4.5) and cirrhotic 
(Figure 4.6) liver samples by immunohistochemistry. Our results revealed 
different staining patterns in normal and cirrhotic livers. 
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 Figure 4. 5 FLT3 Immunohistochemistry of a normal liver. A, B and C are taken with 
different magnifications, 10x, 20x and 40x respectively. D is the negative control. 
(Arrowheads showed FLT3 positive cells) 
 In normal liver, FLT3 positivity was restricted to the cells neighboring the 
ductal structure. The staining observed was cytosolic (Figure 4.5A-C). In addition 
no staining was observed in the hepatocytes. (Figure 4.5A-C) Adversely in 
cirrhotic liver, there was extensive FLT3 staining in hepatocytes, giving a patchy 
appearance (Figure 4.6A-C). FLT3 positivity was found to be mainly cytoplasmic. 
No staining was observed in negative controls (Figure 4.5D and 4.6D) 
 41 
 Figure 4. 6 FLT3 Immunohistochemistry of a cirrhotic liver. A, B and C are taken with 
different magnifications, 10x, 20x and 40x respectively. D is the negative control (Arrow 
heads show some of the positive staining in cirrhotic liver).  
4.3 Functional Analysis of FLT3 in HCCs by Inhibiting 
the Phosphorylation of the Protein with K-252a 
As a tyrosine kinase, FLT3 has been shown to actively participate in a 
wide variety of cellular events such as proliferation and block of apoptosis 
(Stirewalt and Radich, 2003). In this part of my thesis we aimed to investigate the 
function of FLT3 in HCCs. To accomplish this task, we compared the response of 
the cell lines Snu182, Snu398, Huh7, Hep40 before and after treating the cells 
with FLT3 inhibitor, K-252a, which inhibits its phosphorylation. We decided to 
use Snu182, Snu398, Huh7 and Hep40, because they expressed FLT3 in different 
levels (Figure 4.1 and Figure 4.2).  
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4.3.1.  Effect of K-252a on the cellular morphology in HCCs 
 After cells reached 90% confluency, Snu182, Snu398, Huh7 and Hep40 
were treated with 200nM K-252a for two hours. Upon inhibitor treatment, no 
significant change was observed in their morphologies of Snu182 (Figure 4.7A-
B), Snu398 (Figure 4.7C-D), Huh7 and Hep40 (data not shown). 
 
Figure 4. 7   Inverted microscopy photos of Snu182 and Snu398 after 200nM inhibitor 
treatment for two hours. (Magnification: 40x) 
4.3.2 Effect of K-252a on the Subcellular Localization of FLT3 in 
HCCs 
 Since the previous data on liver regeneration showed that, FLT3 changed 
its cellular localization from membrane bound to cytosolic when subjected to PH 
(Aydin et al, 2007), we decided to check the subcellular localization of Snu182, 
Snu398, Huh7 and Hep40, in the presence and absence of FLT3 inhibitor.  
We seeded Snu182, Snu398 Huh7 and Hep40 cells on glass coverslips 
and, treated with 200nM K-252a for two hours prior to fixation. We analyzed 
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FLT3 protein localization with immunofluoroscence before and after the 
treatment with K-252a (Figure 4.8). Our results revealed a drastic change in the 
localization of FLT3 in Snu182 (Figure 4.8A,B), Snu398 (Figure 4.8D,E) and 
Hep40 cell lines (Figure 4.8G,H) and to a lesser degree in Huh7 cells (Figure 
4.8J,K). Upon inhibitor treatment, FLT3 protein was accumulated in the mainly in 
the nucleus and in the endoplasmic reticulum compared to cyoplasmic 
localization without treatment. No staining was observed in negative controls 
(Figure 4.8C, F, I, L). 
 
Figure 4. 8  FLT3 Immunoflouroscence  Snu 182 (A-C), Snu 398 (D-E), Hep40 (G-I) and 
Huh7 (J-K) in the absence (A, D, G, J) and in the presence of 200nM FLT3 tyrosine kinase 
inhibitor K-252a Nocardiopsis sp. (B, E, H, K). Cells were treated with the inhibitor for 2 
hours. Primary Ab was not used in negative controls (C, F, I, L). Nuclei were stained with 
DAPI. (Red arrows point the protein accumulation in the nucleus.) 
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4.3.3 Wound Healing Assay   
 The wound healing ability of cells reflects their invasion capacities. 
Therefore, we performed wound healing assay for Snu182 (Figure 4.9 and 4.10), 
Snu398 (Figure 4.11 and 4.12), and Huh7 (Figure 4.13 and 4.14), in the presence 
and absence of FLT3 inhibitor K-252a, both in normal medium conditions (10% 
FBS) and serum starvation (2% FBS). We were not able to perform this assay in 
Hep40 due to lack of their single cell layer growth. The photographs of the cells 
were taken after with 24-hour periods for 48 hours and the relative healed distance 
is measured from the photographs, which were taken with the same magnification 
each time (Figure 4.9, Figure 4.11 and Figure 4.13). Our results showed that 
Snu182 and Snu398 showed decreased wound healing capacity upon two-hour or 
two-day inhibitor treatment under both normal and serum starved conditions. 
Huh7, on the other hand, didn’t show any significant change in its wound healing 
capacity.  
 
Figure 4. 9 Photographs of wound healing assay for Snu182 under (A) normal medium and 
(B) serum starved conditions and 2-hour inhibitor treatment (i, j, k), 2-day inhibitor 
treatment (l, m, n) and DMSO treatment as a control (o, p, r). (Magnification: 4x) 
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Figure 4. 10 Statistical analysis of Wound Healing Capacity of Snu182 in the presence and 
absence of inhibitor under normal (A, C) and serum starved conditions (B, D). Graphs A 
and B show the relative healed distance and C and D show the average healed distance of 
two experimental groups (p-value: NS between inhibitor treated and control groups). 
 Upon inhibitor treatment, Snu182 showed about 2-fold decrease in its 
healed distance in both normal medium (Figure 4.10A, C) and serum starved 
(Figure 4.10B, D) conditions. Also the two-hour and two-day inhibitor treatment 
showed similar effects. Snu398 also showed a decrease in its invasion ability. The 
decrease in the healing ability is also about 2-fold decrease in its healed distance 
in both normal medium (Figure 4.12A, C) and serum starved (Figure 4.12B, D) 
conditions. 
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Figure 4. 11 Photographs of wound healing assay for Snu398 under (A) normal medium and 
(B) serum starved conditions and 2-hour inhibitor treatment (i, j, k), 2-day inhibitor 
treatment (l, m, n) and DMSO treatment as a control (o, p, r). (Magnification: 4x) 
 
Figure 4. 12 Statistical analysis of Wound Healing Capacity of Snu398 in the presence and 
absence of inhibitor under normal (A, C) and serum starved conditions (B, D). Graphs A 
and B show the relative healed distance and C and D show the average healed distance of 
two experimental groups (p-value: NS between inhibitor treated and control groups). 
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 On the other hand Huh7 didn’t show any significant impairment in its 
invasion ability. Upon inhibitor treatment, the healed distance is similar to the 
distance in the absence of the inhibitor. 
 
Figure 4. 13 Photographs of wound healing assay for Huh7 under (A) normal medium and 
(B) serum starved conditions and 2-hour inhibitor treatment (i, j, k), 2-day inhibitor 
treatment (l, m, n) and DMSO treatment as a control (o, p, r). (Magnification: 4x) 
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Figure 4. 14 Statistical analysis of Wound Healing Capacity of Huh7 in the presence and 
absence of inhibitor under normal (A, C) and serum starved conditions (B, D). Graphs A 
and B show the relative healed distance and C and D show the average healed distance of 
two experimental groups (p-value: NS between inhibitor treated and control groups). 
 
4.3.4 Change in the Epithelial and Mesenchymal Lineage Markers 
After Inhibitor Treatment 
After blocking the phosphorylation of FLT3 with its inhibitor K-252a, we 
observed decreased invasion ability of the cells Snu182, Snu398 and Hep40. We 
thought that this decrease in the invasion might also indicate a decrease in the 
migration of the cells and this could be due to the blocking of EMT. Therefore, 
we collected total RNA from Snu182, Snu398, Huh7 and Hep40, which were 
either treated with K-252a for 2 hours or DMSO. Expression levels of epithelial 
and mesenchymal markers were analyzed in the presence and absence of the 
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inhibitor with RT-PCR. Upon inhibitor treatment, no significant change is 
observed in the expression of any of these markers (Figure 4.15). 
 
 
Figure 4. 15  RT-PCR analysis of Epithelial and Mesenchymal Lineage markers after 200nM 
K-252a treatment for two hours. (A) RT-PCR of E-cadherin, Fibronectin, Vimentin and 
ASMA. GAPDH is used as loading control. (B) Multiplex RT-PCR for Sip-1 and GAPDH. 
GAPDH is used as loading control. 
 
4.3.5 In vitro Programmed Cell Death Analysis and Senescence 
Associated β-Gal Assay 
4.3.5.1 In vitro Programmed Cell Death Analysis 
 In order to understand the mechanism behind the action of the inhibitor on 
FLT3, the induction of apoptosis and senescence in the presence and absence of 
the inhibitor is investigated. Upon inhibitor treatment for two hours, the fold 
changes in the number of apoptotic cells were calculated. 
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Figure 4. 16 The ratio of apoptotic indices of inhibitor treated cells and DMSO treated cells. 
Apoptotic cells were evaluated by TUNEL Assay (p-value: NS between inhibitor treated and 
control groups).  
 Inhibitor treatment caused about two-fold increase in apoptotic cells of 
Snu182 and Hep40, and more than 2-fold increase in Snu398 when compared 
against the number of apoptotic cells in the absence of the inhibitor. But its effect 
on Huh7 is very small (Figure 4.16).   
4.3.5.2 Senescence-Associated β-Gal Assay 
 The role of FLT3 on cellular proliferation was established. Therefore to 
further asses the mechanisms which it exhibits its function, we checked whether 
cells enter to senescence upon inhibitor treatment. Cells that were seeded with 
50% confluency were treated with K-252a for 2 hours prior to the assay. In 
Snu182 some senescent cells were observed but there was no induction of 
senescence after treatment with the inhibitor (Figure 4.17A,B). Snu398 didn’t 
exhibit any senescent cells and this condition didn’t vary with the presence of the 
inhibitor (Figure 4.17D, E).  Huh7 contains more senescent cells compared to 
Snu182 and Snu398, but also no significant change in the number of senescent 
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cell was observed upon 2-hour inhibitor treatment (Figure 4.17G, H).  Finally the 
same case was true for Hep40. Upon inhibitor treatment, no induction in the 
senescence was observed (Figure 4.17J, K). As negative control, SABG solution 
without X-gal was used and no staining was observed (Figure 4.17C, F, I, L). 
 So collectively, FLT3 inhibitor didn’t show any induction of senescence in 
Snu182, Snu398, Huh7 and Hep40. 
 
Figure 4. 17  SABG staining of Snu182, Snu398, Huh7 and Hep40 in the absence (A, D, G, J) 
and presence (B, E, H, K) of the inhibitor. As negative control, SABG solution without X-gal 
is used (C, F, I, L). 
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4.4 In vivo Tumorigenesis 
 Our in vitro data have strongly suggested a role for FLT3 in invasiveness 
of the HCC cell lines that we tested. In this part of my thesis, I aimed to test its 
role in tumorigenesis at the in vivo conditions by using xenograft models in nude 
mice. To investigate the tumor forming ability of Snu182, Snu398, Huh7 and 
Hep40, cells were treated with 200nM K-252a for two hours prior to injection. 
Control cells were treated with equal volume of DMSO for two hours. 6 million 
cells/250μL per animal was injected subcutaneously to male nude mouse. 
Inhibitor-treated cells and control cells were injected subcutaneously into the 
same animal (right and left side of the dorsal region of the mice, respectively). 
Our results showed that Snu182 injected animals didn’t form any tumors for a 
time course of 3 months. Snu398 injected animals showed fastest tumor 
formation. Inhibitor treated Snu398 cells didn’t showed any tumor, where the 
control cells formed tumors two weeks after injection (Figure 4.18 and Figure 
4.21). Figure 4.18 shows the growth of the tumors after injection. Figure 4.21 on 
the other hand shows the average sizes of the tumors of all the animals that 
formed tumors after injection. The difference between the tumor forming abilities 
of inhibitor treated and control cells of Snu182 are significant with a p-value of 
0.045 (Figure 4.21). 
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Figure 4. 18 Xenograft Tumors of Snu398. In the graph, growth of the tumor volume can be 
observed. In the photographs, tumors of three different nude mice are seen. (Blue arrows: 
DMSO treated cells’ injection site, Red arrows: K-252a treated cells’ injection site) 
 Similarly, Hep40 cells also showed significant difference in tumor 
formation in the absence and the presence of the inhibitor. Tumors at sites where 
control cells of Hep40 were injected started to appear 2 weeks after injection 
(Figure 4.19). Hep40 cells treated with inhibitor also formed tumors but the sizes 
of the tumors are significantly (p-value: 0.009) smaller than the tumors formed by 
the control cells (Figure 4.21). 
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Figure 4. 19 Xenograft Tumors of Hep40. In the graph, growth of the tumor volume can be 
observed. In the photographs, tumors of three different nude mice are seen. (Blue arrows: 
DMSO treated cells’ injection site, Red arrows: K-252a treated cells’ injection site) 
 On the other hand, Huh7 injected animals didn’t give any significant 
results (Figure 4.21). Tumors appeared later than Snu398 and Hep40, on day 35 
after injection and there wasn’t any significant difference between the sizes of 
tumors formed by inhibitor treated cells or control cells. On day 55 after the 
injection, one of the animals with Huh7 tumors had to be euthanized due to the 
tumors necrosis. Figure 4.20 shows the growth of the tumors until day 55. But the 
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recording of tumor sizes continued form the remaining animals and the remaining 
animals showed larger tumors in sites where inhibitor treated cells were injected 
(data not shown). 
 
Figure 4. 20 Xenograft Tumors of Huh7. In the graph, growth of the tumor volume can be 
observed. The average tumor volume of 4 animals until day 55 was shown. 
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Figure 4. 21 Average tumor volumes of xenografts injected with Snu398, Hep40 and Huh7 
cells in the presence or absence of inhibitor. (*: p-value=0.045, **: p-value=0.009) 
 
These results indicate that; inhibitor treatment of Snu398 and Hep40 
showed significant impairment in the tumor forming ability of these cell lines, but 
it has no significant effect on Huh7. These results are also consistent with the in 
vitro invasion capacities of the cell lines.  
 Collectively our results indicate that FLT3 plays an important role in 
hepatocellular carcinogenesis. 
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5. Discussion 
5.1 Discussion 
 Liver is the one of the vital organs in the body and has been an interest for 
research even in ancient times. Its important biological functions, such as 
detoxification and regenerative capacity differentiate liver from many other 
organs in the body. Therefore it is not surprising that hepatocellular carcinoma is 
one of the most lethal cancers all over the world. In addition, consistent 
biomarkers to characterize HCCs and different stage liver diseases ranging from 
regenerating liver, fibrosis and cirrhosis are missing. Lack of biomarker is one of 
the main obstacles behind good diagnostic and prognostic tools. The only cure of 
end-stage liver diseases is liver transplantation, however the need for organ for 
transplantation is by far less than the availability (http://organdonor.gov). As of 
July 2010, there are 108,091 patients who are waiting for the transplant. The 
number of the donors for the period of January-March 2010 was only 3,440. 
Therefore the need for biomarker for early diagnosis is more than ever. Such 
markers can also be good candidates against targeted therapeutical approaches. 
 Molecular characterization of HCCs is very important, since its 
characterization is the indicator of the prognosis of the disease.  There are recent 
microarray based comparative genomic researches aimed to identify a molecular 
structure for HCCs of different stages (Colak et al, 2010).  Today the major 
characterization of HCC is based on the Alfa-feta protein expression levels and 
the stemness of the tumor cells, which gives the definitions of WD and PD (Qin 
and Tang, 2002). However, this characterization is too wide to be used as a 
marker for diagnostic and therapeutic purposes. We adopted a different rationale 
to identify a candidate marker in hepatocellular carcinogenesis. We focused on 
FLT3 in order to differentiate between HCCs for the following reasons: 
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i) Involvement of tyrosine kinases in development of malignancies 
(Lemmon and Schlessinger, 2010) 
ii) By our group FLT3 has been shown to play a role during liver 
regeneration (Aydin et al, 2007) 
iii) Close relation of hematopoietic stem cells during liver 
development and hematopoiesis (Kinoshita et al, 1999) indicates 
that FLT3 might also function during liver development. 
iv) Role of FLT3 in AML (Thiede et al, 2002 and Nakao et al, 1996) 
Therefore, first we analyzed the expression level of FLT3 in 14 HCC cell 
lines.  Our data showed that FLT3 was expressed in Snu182, Snu398 (PD) and 
Hep40 (WD) on mRNA level and in Hep3B, Hep40 (WD) and Focus, SK-Hep1, 
Snu182, Snu387 and Snu398 (PD) on protein level (Figure 4.1 and Figure 4.2). 
These results suggest that there is no correlation between the expression of FLT3 
and the differentiation status of the HCC cell lines. Thus, after checking the 
expression of FLT3, we wanted to analyze these 14 HCC cell lines for expression 
of a range of stem cell markers and epithelial and mesenchymal lineage markers.  
One of the markers that we analyzed was CD133, which is a 
hematopoietic progenitor marker. More importantly it is highly associated with 
cancer stem cells, where the subpopulations of CD133+ cells are able to form 
tumors in xenograft models. Although it is related to stemness properties, it was 
interesting to observe its expression in WD HCC cell lines (HepG2, Hep3B, 
Hep40, Huh7 and PLC). This could be an indication for the presence of cancer 
stem cells in these well-differentiated HCC cell lines. In fact the presence of a 
CD133+ subpopulation of cells was shown to be tumorigenic in Huh7 cell line 
(Yin et al, 2007). Besides the WD HCCs, PD HCC cell lines (Mahlavu, Focus, 
Snu182 and Snu449) showed CD133 expression.  Since the PD HCC cell lines 
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resemble stem cells, it is reasonable to observe the expression of CD133, but 
whether this expression comes form a subpopulation of cells that could be 
inferred as cancer stem cells or the expression is universal should be investigated 
(Figure 4.3). 
The second marker that we analyzed is CD90, which is a mesenchymal 
stem cell marker. We observed its expression mainly in PD HCC cell lines 
(Focus, SK-Hep-1, Snu387 and Snu398). The expression of CD90 could also be 
used to differentiate WD and PD HCCs, in order to predict the prognosis of the 
disease (Figure 4.3). 
Thirdly, we performed RT-PCR for LGR5.  LGR5 is an orphan G-protein 
coupled receptor, which was initially identified as a marker of stem cells in +4 
position of the intestinal crypts (Barker et al, 2007). This adult stem cell marker 
was then found to be expressed in many other organ’s adult stem cells ranging 
from colon to hair follicle and in some cancer types such as colorectal cancer 
(Barker et al 2008). These evidences also suggests that LGR5 can also be used the 
characterize HCC cell lines, both because of its indication of stem cell properties 
(Figure 4.3).   
Since there is a close correlation between liver development and 
hematopoiesis, where fetal liver is the site for hematopoiesis (Kinoshita et al, 
1999), we analyzed the expression levels of some hematopoietic markers. All the 
cell lines tested were negative for CD45 and only Snu182 showed expression of 
CD34. This suggests that Snu182, which is a poor differentiated HCC, resembles 
the early progenitors of hepatic cells and hematopoietic cells (Figure 4.3). 
Also this expression analysis revealed an interesting relation between 
Snu182 and Snu398. Although these two cells lines are FLT3 positive both on 
mRNA and protein level, when the expressions of other markers are analyzed, 
they have showed different characteristics. Snu182 is positive for CD133, LGR5 
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and CD34 where Snu398 is positive for CD90 and negative for the rest of the 
markers.  This could indicate that FLT3 might be a marker of different types of 
HCCs with different molecular characteristics, which widens its diagnostic and 
therapeutic applications. 
For further characterization, we analyzed epithelial and mesenchymal 
lineage markers. EMT is a very important process during development and 
cancer. By analyzing the expression of some epithelial and mesenchymal lineage 
markers, it is aimed understand the different stages of hepatocellular 
carcinogenesis and the consequence of epithelial or mesenchymal originated cells 
to the outcome of the cancer.  The mesenchymal lineage markers vimentin and α-
SMA didn’t reveal any expression differences between 14 HCC cell lines. On the 
other hand fibronectin, which is also a mesenchymal lineage marker, was 
expressed in all of the cell lines, but its expression varies. E-cadherin’s expression 
is restricted to WD HCC and Snu182. Snu182 and Snu398 again showed different 
characteristics, where Snu182 is E-cadherin positive and highly expressed 
fibronectin and Snu398 is E-cadherin negative and slightly expressed fibronectin 
(Figure 4.4).  Also the co-expression of both epithelial and mesenchymal markers 
indicates that these cell lines contain heterogeneous cell populations. This 
situation resembles the in vivo, where the tumors have heterogeneity (An et al, 
2001).  
After the characterization of HCC cell lines, we also checked the 
expression pattern of FLT3 in normal (Figure 4.5) and cirrhotic (Figure 4.6) liver 
human tissue sections. In normal liver, FLT3 is only observed in cells near the 
ductal structure, which might be the progenitor cells of the liver (Sell and Leffer, 
2008). But on the other hand, we observed an extensive patchy appearance of 
cytoplasmic FLT3 expression by the hepatocytes in cirrhotic liver. But to further 
conclude that FLT3 expression varies between regenerating, fibrotic, cirrhotic 
livers and HCC, a larger array of tissue sections are needed. 
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The subcellular localization of FLT3 infers some functional differences. 
Previous results had shown that upon PH, in a rat liver regeneration model, 
membrane bound FLT3 becomes cytoplasmic (Aydin et al, 2007). Interestingly 
our immunofluoroscent staining has shown that FLT3 has a nuclear staining in 
Snu182, Snu398 and Hep40 (Figure 4.8). FLT3-ITD mutants also showed an 
abnormal localization, in perinuclear regions and in different compartments of 
secretory pathway (Koch et al, 2008). These results indicate that the localization 
of the protein might cause differences in its functionality.  
After the characterization of the cell lines and identifying the localization 
of FLT3 in liver sections and cell lines, we decided to perform functional analysis 
of FLT3, which is necessary to link the expression of the protein with 
hepatocellular carcinogenesis. For this purpose, we used FLT3 inhibitor K-252a, 
which blocks the signal transduction of the protein via blocking its 
phosphorylation. First of all, whether the subcellular localization of the protein 
changes after the inhibitor treatment is checked. Interestingly, blocking the 
function of the FLT3 with K-252a caused the protein to more accumulate in the 
nucleus and endoplasmic reticulum, as opposed to the membrane bound 
localization expected (Figure 4.8). This suggests that FLT3 has an auto-regulatory 
role in the sorting of the protein. Also these results support the conclusion where 
the localization of the proteins is important for its function. 
To further analyze the involvement of FLT3 in HCC progression, we used 
an in vitro invasion assay, wound healing assay. We performed the assay with 
normal medium conditions (10% FBS) and under low serum conditions, which we 
referred as serum starvation (2% FBS) throughout the thesis. By serum starving 
the cells, we stop their proliferation and therefore aim to see only the invasion of 
the cells. After the wounds were made, cells were treated with the FLT3 inhibitor 
for two hours or for two days. Our results revealed that Snu182 and Snu398 
showed an approximate of two fold decrease in their invasion capacity under the 
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influence of the inhibitor for both 2 hours and 2 days (Figure 4.10 and Figure 
4.12). Also the results are consistent for both serum starvation and normal 
medium, which indicates that the effect is not due to stalled proliferation but due 
to the invasion of the cells. On the other hand, we couldn’t observe any change in 
the invasion capacity of Huh7 in the presence and in the absence of the inhibitor 
(Figure 4.14).  This result is expected, since Huh7 didn’t express FLT3. This 
negative control also indicated that the effect of the inhibitor is more or less 
specific to FLT3 phosphorylation. 
This invasion capacity might also be an indicator for migration capacity of 
the cells. After inhibitor treatment, any change that occurs in the expression of 
epithelial and mesenchymal markers could indicate the process of EMT/MET, 
which could explain the role of FLT3 in the metastasis of the cells. Recently, 
EMT has been shown to play an important role in hepatocellular carcinogenesis 
(Choi and Diehl, 2009). Upon inhibitor treatment, we did not observe any change 
in the expression levels of these markers suggesting that the role of FLT3 on 
tumorigenesis is not through inducing EMT (Figure 4.15). New studies such as in 
vitro migration assays are warranted to clarify this issue. 
FLT3 has proliferative and anti-apoptotic roles. Its signal transduction 
involves the inhibition of apoptotic genes and activation of MAPK and PI3K 
pathways (Stirewalt and Radich, 2003). To see whether there will be any change 
between the number of apoptotic cells in the absence and the presence of the 
inhibitor, we performed TUNEL assay.  Upon inhibitor treatment we observed 
about 2-fold increase in the number of apoptotic cells in Snu182, Snu398 and 
Hep40. As in the case of wound healing assay results, Huh7 didn’t show any 
change in the number of apoptotic cells (Figure 4.16). These results indicate that 
activating anti-apoptotic mechanisms is could be one of the mechanisms FLT3 
contributes to tumorigenesis in vivo. This case was also shown for the case of 
AML, where 25-45% of the AML patients have a constitutively activating 
 63 
mutation of FLT3 (Stirewalt and Radich, 2007). A study in AML, treatment with 
a different FLT3 inhibitor (PKC412) showed increased apoptosis. Also the same 
study showed that using a FLT3 inhibitor, in combination with drug that induces 
apoptosis (C-28 methyl ester of the oleane triterpenoid) increases the apoptosis 
(Ahmad et al, 2010). This suggests that combinations of therapies that include 
FLT3 inhibitors and other chemotherapeutic agents can also be used in different 
types of HCCs. 
Since FLT3 signaling also activates pathways related to proliferation, we 
checked whether absence of this signaling induces senescence.  We performed 
senescence-associated β-Gal assay after 2-hour inhibitor treatment. We used 
DMSO for control treatments. Our results show no difference in any of the cell 
lines (Snu182, Snu398, Huh7 and Hep40) between the inhibitor treated cells and 
control cells (Figure 4.17). This indicates that the tumorigenesis of FLT3 is not 
supported by inactivation of senescence.  
Our in vitro data suggest the involvement of FLT3 in the invasiveness of 
the HCC cell lines, but EMT does not occur during this process. To see whether it 
has a role in tumorigenesis, we used xenograft models in nude mice. Snu398 
formed tumors only with the control cells but no tumors are formed at the site of 
injection of inhibitor treated cells (p-value: 0.045). Hep40 cells formed 
significantly smaller tumors in inhibitor treated samples (p-value: 0.009)(Figure 
4.21). These data provide strong evidence to the involvement of FLT3 in 
hepatocellular carcinoma formation in vivo. Subcutenous injection of Huh7 cells, 
on the other hand, formed tumor with inhibitor-treated and control-treated groups, 
but there was no significant difference in terms of tumor sizes. Interestingly, 
Snu182 cells didn’t form any tumors. The reason of the discrepancy in terms of 
the tumor formation between Snu398 and Snu182 might be due to the differences 
of the expressions of the markers that we tested in this thesis.  Besides the 
expression of FLT3, all the markers showed different expression patterns in 
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Snu182 and Snu398 cell lines (Table 5.1). As seen from this table, Snu182 was 
positive for CD133. This data might be seen as controversial since CD133 is a 
cancer stem cell marker, however it is in parallel with a recent study which 
showed that expression of cancer stem cells markers cannot be considered as the 
only prognostic parameters in HCCs (Salnikov et al, 2009).  
Figure 5.1 briefly summarizes the relations between FLT3 throughout the 
progression of HCC from normal liver. In normal liver, FLT3 is expressed only in 
progenitor cells. Upon injury, it is changes its localization and participates in the 
regeneration process (Aydin et al, 2007). We have shown that FLT3 is extensively 
expressed by the hepatocytes in cirrhotic liver, with a patchy appearance in the 
tissue.  
 
Figure 5. 1 FLT3’s involvement during different stages leading to HCC. The question marks 
in the figure indicate the areas where we need further investigation. Green arrows belong to 
the relations mentioned and revealed in this thesis. 
Our findings of in vitro and in vivo experiments are summarized in Table 
5.1. Collectively, our results revealed that FLT3 contributes to hepatocellular 
carcinogenesis as shown by both in vitro and in vivo assays. Also, its expression 
in HCC cell lines together with different molecular subtypes (with different 
marker expression) indicates that it can be a diagnostic tool for HCCs from 
different stages. As in the case of AMLs it can also be a good therapeutic 
candidate for the treatment of HCCs, since blocking its activity showed severe 
impairment in the tumor forming ability.  
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Table 5. 1 Findings of in vitro and in vivo experiments 
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5.2 Future Perspectives 
 Our data in this thesis provide essential information regarding the role of 
FLT3 in hepatocellular carcinogenesis. In order to have an entire picture of 
molecular mechanisms of HCC development and FLT3, it is imperative to extend 
our studies in the following direction as depicted in figure 5.1: 
• FLT3 in fibrotic livers should be further analyzed with tissue samples 
from varying stages of fibrotic and cirrhotic livers.  
• Although significant results were obtained with FLT3 inhibitor, siRNA 
knockdown studies should be performed against FLT3. Migration and  
invasion assays as well as in vivo xenograft experiments should be 
performed after knocking down the FLT3 with lentiviral systems in order 
to better understand the role of this protein during hepatocarcinogenesis. 
• FLT3 mutations were found in many AML patients, to check whether 
FLT3 is also mutated in HCCs, mutational analysis should be performed 
for FLT3 for the most common constitutively activating mutations. 
• Finally, crosstalk between FLT3 signaling and immune response should 
also be explored in order to shed light into the mechanism of 
hepatocarcinogenesis. Role of TLRs during this process would provide 
important information to design appropriate therapeutic approaches to 
tackle HCC.  
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7. Appendix 
STANDARD SOLUTIONS AND BUFFERS 
DEPC-Treated ddH2O  
1ml DEPC 
1lt ddH2O 
Stirred in a hood for 1 hour, autoclaved in order to inactivate the DEPC 
10x PBS 
80 g NaCl 
2 g KCl 
8,01g Na2HPO4.2H2O 
2g KH2PO4 
1 liter ddH2O pH: 7,2 
Working solution (1XPBS) was prepared by diluting 10XPBS by 10 times 
50X TAE Buffer 
2M Tris Base (242 g) 
57,1 ml Glacial Acetic Acid 
50mM EDTA 
Add to 1 lt by ddH2O  
Working solution (1XTAE) prepared by diluting 50XTAE. 
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10 X Agarose Gel Loading Dye 
0,009g BFB 
0,009g XC 
2,8mL ddH2O 
1,2ml 0,5M EDTA. 
Total volume brought to 15ml by adding glycerol, dilute 1:10 in sample 
prior to loading to electrophoresis gel 
10%SDS 
100g SDS  
1lt ddH2O 
1M Tris 
60.55g Tris  
300ml ddH2O 
21ml 37% HCl 
pH adjusted to 8.0 with HCl, total volume brought to 500ml by adding 
ddH2O. 
0.5M EDTA 
93.05g EDTA  
300ml ddH2O 
pH adjusted to 8.0 with NaOH, total volume brought to 500ml by adding 
ddH2O. 
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30% Acrylamide Mix 
145g Acrylamide  
5g bis-acrylamide 
500ml ddH2O 
Filtered, stored in dark at 40C. 
SDS-PAGE Running Buffer (5X stock solution) 
15g Tris 
73,2g Glycine 
5g SDS 
1lt ddH2O 
1X working solution prepared by diluting the 5X SDS-PAGE running 
buffer 5 times, stored at 40C  
Bradford Reagent 
100 mg Coomassie Brilliant Blue G-250  
100 ml 85%phosphoric acid 
50 ml 95%EtOH 
850 ml ddH2O 
Filtered through Whatman no:1 
 
 
 79 
Lysis Buffer 
2M NaCl 
1M Tris pH:8.2 
0.9% Igepal CA-630 (Sigma, Germany) 
10x Protease Inhibitor Cocktail (Roche, Germany) 
778.5µl ddH2O 
10X TBS 
12.19 g Tris 
87,76 g NaCl 
pH adjusted to 8, total volume brought to 1lt by adding ddH2O 
1X TBS-T 0.1% 
50 ml 10X TBS 
450 ml ddH2O 
1ml Tween-20 
Total volume brought to 500ml by adding ddH2O 
Blocking Solution for Western Blot (5%) 
2,5 g milk powder 
50mL 1X TBS-T(0.1%) 
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5% BSA Blobking Solution 
0.5g BSA 
10mL 1X TBS-T(0.1%) 
Blocking Solution for Immunohistochemistry and 
Immunoflourescence Staining 
4 µl 2% BSA 
4 µl 1X PBS 
20 µl Tween-20 
1XPBS-T (0.1%) 
500ml 1XPBS 
0.5ml Tween-20 
Cracking Buffer (2X Protein Loading Buffer) 
50mM Tris HCl pH: 6,8 
2mM EDTA pH: 6,8 
1% SDS 
20% Glycerol 
0,02% BFB 
Add 1% ß-mercaptoethanol prior to use 
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Coomassie Blue Staining Solution: 
0,25 g coomassie brilliant blue 
45 ml Methanol 
45 ml ddH2O 
10 ml glacial acetic acid 
5X Running Buffer 
15 g Tris base 
72 g Glycine 
5 g SDS 
1 liter ddH2O 
Diluted to 1X prior to use 
Semi-dry Transfer Buffer 
2,5 g glycine 
5,8 g Tris base 
0,37 g SDS 
200 ml methanol 
800 ml ddH2O 
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Wet Transfer Buffer 
9g Tris Base 
43.2g Glycine 
300mL Methanol 
1.5mL 10%SDS 
Complete volume to 1.5L. 
Destaining Solution 
100 ml methanol 
35 ml acetic acid 
365 ml ddH2O 
Sodium Citrate Buffer 
 10mM Sodium Citrate, 0.05% Tween-20 
 Adjust pH to 6.0 
 
